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Summary 
 
The N-methyl-D-aspartate (NMDA) receptor is a ligand gated ion channel and belongs 
to the ionotropic glutamate receptor (iGluR) family. The NMDA receptors play a unique 
role among the iGluRs because of their high Ca2+ permeability and their 
heterotetrameric assembly. They are central to development and function of the 
nervous system and are involved in processes like learning and memory. Impairment of 
NMDA receptors is associated with a wide spectrum of neurological diseases and 
because of their crucial role in brain development they are of great interest in 
pathophysiological conditions. NMDA receptors are composed of two obligatory GluN1 
subunits and two GluN2(A-D) or GluN3(A,B) subunits. Each subunit has modular 
domains which are responsible for controlling distinct functions. The extracelluar N-
terminal domain (NTD) has a modulatory function and contains binding sites for 
allosteric ligands like zinc. The ligand binding domain (LBD) contains the agonist 
binding sites and is connected with the transmembrane domains (TMD). The three 
TMDs (M1, M2, M3) and the re-entrant pore loop (P-loop) contribute to the formation of 
the core of the ion channel. The pore loop includes the QRN site, which builds the 
narrow constriction of the pore and is essential for permeation properties of the 
receptor. 
One objective of this work was to analyze the NMDA receptor in pathological 
conditions, especially the influence of the allosteric modulation mediated through the 
NTD and the pore region referring to Mg2+ block and Ca2+ permeability. In cooperation 
with clinical groups we got information about mutations in NMDA receptor subunits 
from patients with different forms of epilepsy. Selected mutations in the NTD and the 
ion channel pore were used for site-directed mutagenesis and subsequent functional 
characterization by two-electrode-voltage-clamp in Xenopus laevis oocytes.  
The investigation of different mutations revealed strong effects on ion channel function. 
Modifications of the NTD and the channel pore region led to a gain of function through 
impairment of different inhibition mechanisms. In the case of the NTD mutation GluN2A 
p.Ala243Val a loss of Zn2+ inhibition occurred. The pore mutations GluN2A 
p.Asn615Lys, GluN2B p.Asn615Ile and p.Val618Gly revealed also a reduced Mg2+ 
block and higher relative Ca2+ permeability. The gain of ion channel function could be a 
reasonable molecular correlate for the epilepsy syndromes because it results in an 
overactivation of the receptors, which in neuronal networks could lead to 
hyperexcitation in excitatory neurotransmission. This is in concordance with the  
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hypothesis that epilepsy proceeds from hyperexcitation.  
 
Thus GluN1/GluN2A,B NMDA receptors antagonists are promising tools for treatment 
of neurological disorders, which results from hyperexcitation, like epilepsy. To validate 
the potential use of GluN1/GluN2 antagonists in disorder treatment, the effect and 
mechanism of different GluN1 antagonist at the excitatory GluN1/GluN3A NMDA 
receptor subtype was analyzed. In contrast to conventional NMDA receptors, 
antagonizing the GluN1 binding site results in GluN1/GluN3A receptors in an enhanced 
receptor activation. The analysis of several GluN1 antagonists showed a correlation of 
the extend of GluN1/GluN3A receptor current increase and the affinity of the respective 
antagonist. Thus, the results revealed a direct relationship between antagonist affinity 
and potentiation efficacy.  
 
In summary this work presents mutations in the GluN2A and GluN2B subunit of the 
NMDA receptors as important genetic determinants of some severe forms of age-
related epilepsies. The findings reveal strong evidence of the strong contribution of 
altered NMDA receptor signaling to epileptogenesis. Subsequent the data creates the 
possibility for NMDA receptors as new targets in epilepsy treatment with NMDA 
blockers and antagonists, but also reveal the complexity of antagonist impact on the 
different NMDA receptor subtypes.  
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Zusammenfassung 
 
Der N-methyl-D-aspartate (NMDA) Rezeptor ist ein ligandengesteuerter Ionenkanal 
und gehört zur Familie der ionotropen Glutamatrezeptoren (iGluR). Aufgrund seiner 
hohen Ca2+-Leitfähigkeit und seiner heterotetrameren Assemblierung spielt der NMDA 
Rezeptor innerhalb der iGluRs eine besondere Rolle. Für die Funktion sowie in der 
Entwicklung des zentralen Nervensystem, spielen diese Rezeptoren eine zentrale 
Rolle. Weiterhin sind sie an Prozessen wie Lernen und Gedächtnisbildung beteiligt. 
Eine Schädigung von NMDA Rezeptoren wird mit einer Reihe von neurologischen 
Erkrankungen in Verbindung gebracht und aufgrund ihrer wichtigen Rolle für die 
Gehirnentwicklung sind sie von großem Interesse in pathologischen 
Zusammenhängen.  
NMDA Rezeptoren sind aus zwei obligaten GluN1 und zwei GluN2(A-D) oder 
GluN3(A,B) Untereinheiten aufgebaut. Jede dieser Untereinheiten weist einen 
modularen Aufbau mit verschiedenen Domänen auf, welche für unterschiedliche 
Funktionen zuständig sind. Die extrazellulär gelegene N-terminale Domäne (NTD) hat 
eine modulierende Funktion und besitzt Bindestellen für allosterische Modulatoren, wie 
beispielsweise Zink. Die Liganden-Bindungs-Domäne (LBD) beinhaltet die Agonisten-
Bindestellen und ist mit den Transmembrandomänen (TMD) verbunden. Die drei 
Transmembrandomänen (M1, M2, M3) und die Wiedereintrittsschleife (P-Loop) bilden 
die Ionenkanalpore. Die Pore wird durch die QRN Stelle verengt, welche entscheidend 
für die Permeationseigenschaften des Rezeptors ist. 
Ein Ziel der Arbeit war die Analyse des NMDA Rezeptors in pathologischen 
Zusammenhängen. Dabei wurde der Einfluss der allosterischen Modulation, welcher 
über die NTD vermittelt wird, untersucht. Weiterhin wurde der Einfluss der Porenregion 
bezüglich des Mg2+-Blocks und der Ca2+-Permeabilität analysiert. In Zusammenarbeit 
mit klinischen Arbeitsgruppen erhielten wir Informationen über Mutationen in 
verschiedenen NMDA Rezeptor Untereinheiten, aus Patienten mit verschiedenen 
Epilepsie-Syndromen. Für die Analyse wurden einzelne Mutationen in der NTD und der 
Ionenkanalregion ausgewählt und mittels zielgerichteter Mutagenese eingeführt. 
Anschließend erfolgte die funktionale Charakterisierung der ausgewählten Mutationen 
mittels der Zwei-Elektroden-Spannungsklemme (Two-electrode-voltage-clamp, TEVC) 
an Xenopus laevis Oozyten.  
Die elektrophysiologischen Analysen der verschiedenen Mutationen in der NTD und  
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der Kanalpore zeigten eine Verstärkung (gain of function) der Ionenkanalfunktion durch 
eine Verminderung verschiedener Inhibitionsmechansimen. Die Mutation GluN2A 
p.Ala243Val in der NTD führte zu einem Verlust der Zn2+-Inhibition. Die Mutationen in 
der Kanalregion führten zu einer starken Verringerung des spannungsabhängigen 
Mg2+-Blocks sowie höheren, relativen Ca2+-Permeabilitäten. Diese Verstärkung (gain of 
function) der Ionenkanalfunktion könnte ein molekulares Korrelat für die Epilepsie-
Syndrome darstellen, wodurch es zu einer Überaktivierung der Rezeptoren kommt. In 
neuronalen Netzen könnte dies zu einer Übererregung (Hyperexzitabilität) der 
exzitatorischen Neurotransmission führen. Dies würde mit der Hypothese 
übereinstimmen, dass Epilepsie durch Übererregung ausgelöst werden kann. 
Aus diesem Grund sind GluN1/GluN2A,B NMDA Rezeptor Antagonisten für die 
Behandlung neurologischer Erkrankungen, welche durch eine Übererregung ausgelöst 
werden, wie beispielsweise. Epilepsie, ein vielversprechender Ansatz. Um den 
möglichen Einsatz von GluN1/GluN2 Antagonisten in der Behandlung von 
neurologischen Erkrankungen zu validieren, wurden der Effekt und der Mechanismus 
verschiedener GluN1 Antagonisten an exzitatorischen GluN1/GluN3A NMDA 
Rezeptoren untersucht. Im Gegensatz zu den konventionellen NMDA Rezeptoren führt 
eine Antagonisierung der GluN1-Bindestelle zu einer verstärkten Rezeptoraktivierung. 
Die elektrophysiologische Analyse verschiedener GluN1 Antagonisten zeigte eine 
Korrelation zwischen der Potenzierung der GluN1/GluN3A Rezeptor-Ströme und der 
Affinität des jeweiligen Antagonisten. Diese Ergebnisse zeigten somit einen direkten 
Zusammenhang zwischen der Antagonistenaffinität und der Potenzierungseffizienz.  
 
Zusammenfassend präsentiert diese Arbeit Mutationen in der GluN2A und GluN2B 
Untereinheit des NMDA Rezeptors als wichtige, genetische Determinanten, in einigen 
schweren, altersabhängigen Epilepsien. Diese Ergebnisse sind deutliche Hinweise für 
eine starke Beteiligung von veränderter NMDA-Rezeptor-Signalübertragung an der 
Epileptogenese. Weiterhin eröffnen diese Daten die Möglichkeit NMDA Rezeptoren als 
neue Ziele in der Epilepsie-Behandlung zu nutzen und mit Blockern und Antagonisten 
zu behandeln, aber zeigt zugleich die Komplexibilität des Einflusses von Antagonisten 
auf NMDA Rezeptoren. 
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1 Introduction 
Glutamate receptors are responsible for the fast excitatory synaptic transmission in the 
central nervous system (CNS) and are involved in many brain functions. They are 
activated through glutamate and are subdivided in two main classes: the metabotropic 
and the ionotropic glutamate receptors. The ionotropic glutamate receptors again are 
grouped into four classes based on the pharmacology and structural homology: the 
(RS)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid receptors (AMPARs), 
the kainate receptors (KARs) and the N-methyl-D-aspartate receptors (NMDARS). The 
NMDA receptors are essential in development and play a major role in neuronal 
excitation in the CNS. Impairment of NMDA receptors is associated with a spectrum of 
neurological diseases like schizophrenia, Alzheimer disease, cognitive impairment, 
depression and pain. Several characteristic properties of NMDA receptors distinguish 
them from other ionotropic receptors.  
 
 
1.1 Characterization of NMDA receptors 
NMDA receptors are encoded by seven different genes: GRIN1, GRIN2A-D, GRIN3A 
und GRIN3B (Cull-Candy et al., 2001; Dingledine et al., 1999). Whereas the GRIN1 
gene undergoes alternative splicing to generate eight different isoforms (Monyer et al., 
1994), the other subunits are encoded by six separate genes. NMDARs are integral 
membrane proteins, which assemble as heterotetrameric complexes and form a cation 
selective ion channel. The so called “conventional“ NMDA receptors are composed of 
two obligate glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits 
(Monyer et al., 1992; Furukawa et al.,2005). The agonist glutamate and glycine are 
both required to activate GluN1/GluN2 receptors. The channel pore of these receptors 
conduct Na+ and K+ and is highly permeable to Ca2+ ions. The influx of Ca2+ leads to an 
activation of Ca2+-dependent second messenger cascades and is important for 
processes like learning and memory (Burnashev N, 1995 ; Mayer and Westbrook, 
1987). Furthermore NMDAR currents display a strong voltage dependency due to the 
Mg2+ block in the channel pore and in comparison with AMPA and kainate receptors, 
NMDARs show slow activation and deactivation kinetics. A further hallmark of NMDA 
receptors is the wide spectrum of allosteric modulation. There are various extracellular 
compounds to modulate NMDA receptor activity such as zinc (Zn2+), ifenprodil,  
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polyamines and protons (H+), acting as allosteric modulators and voltage dependent 
channel blockers MK-801, ketamine and memantine.  
The last detected GluN3A and GluN3B subunits are the third member of the NMDA 
family, which shares many characteristics of the NMDA family, but also provides 
different properties to NMDA receptors in comparison to the conventional ones. These 
“unconventional” NMDA receptors display a different pharmacological profile. The 
GluN3 subunits can coassemble with GluN1 subunits and because of the absence of a 
glutamate-binding site, these receptors can be activated solely by glycine (Awobuluyi et 
al., 2007; Chatterton et al., 2002; Madry et al., 2007). Therefore, they are also called 
excitatory glycine receptors. Furthermore, when coassembled with GluN1 and GluN2 
subunits, GluN3A exerts a dominant-negative effect on NMDA properties. Incorporating 
of the GluN3A subunit decreases single channel conductance, Ca2+ permeability and 
Mg2+ block in vitro and in vivo (Cavara et al., 2010; Chatterton et al., 2002; Matsuda et 
al., 2003; Perez-Otano et al., 2001; Sasaki et al., 2002; Tong et al., 2008). Also the 
modulation of GluN1/GluN3A receptors shows differences. Coapplication of Zn2+, which 
acts on GluN2 subunits and inhibit the conventional NMDA receptors, can act as a 
positive modulator and also as an agonist at GluN1/GluN3A receptors (Madry et al., 
2008). Furthermore, GluN1 antagonists, which inhibit GluN1/GluN2 receptors, lead to 
an enhancement of GluN1/GluN3A receptor activation (Madry et al., 2007). In 
comparison to GluN1/GluN2 NMDA receptors the role of the GluN3 subunits is less 
well defined and further studies are needed to elucidate the role of these GluN1/GluN3 
receptors. 
 
 
1.2 NMDA receptor subunit structure 
Like AMPA and Kainate receptor, all NMDA subunits have a typical modular 
organization consisting of four functional domains: the N-terminal domain (NTD), the 
ligand binding domain (LBD), a transmembrane domain (TMD) comprised of three 
transmembrane helices (M1, M2, M3) and a re-entrant pore loop (P-loop), and an 
intracellular C-terminal domain (CTD) (Fig 1.1). The amino acid sequences of the NTD 
and LBD are homologous to two families of bacterial binding proteins (Armstrong et al., 
1998; Nakanishi et al., 1990; O'Hara et al., 1993), what suggests a common 
phylogenetic origin. The NTD is related to the leucine-isoleucine-valine binding protein 
(LIVBP) and has a modular function. This domain shows a bilobed, clamshell like  
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structure which, is formed by an upper R1 and a lower R2 lobe and is involved in 
subunit assembly (Karakas 2009, Farina 2011). Furthermore, the GluN2 NTDs contain 
binding sites for allosteric modulators such as Zn2+ and Ifenprodil. The LBD shows 
sequence homology with the bacterial glutamine-binding protein and contains the 
agonist binding sites. Crystallographic studies revealed the typical bilobed, clamshell-
like structure with the agonist glycine in GluN1 and GluN3 and glutamate in GluN2 
subunits. The clamshell-like structure is formed by two extracellular segments, S1 and 
S2. The LBD is connected through three short linkers to the TMD. The TMD contributes 
to the formation of the core of the ion channel and has high sequence homology with 
the inverted ion channel domain of K+ channels (Kuner et al., 2003; Wo and Oswald, 
1995). The region lining the pore is highly conserved, important for permeation 
properties and the affinity for the pore blocker Mg2+. The intracellular CTD is the most 
diverse domain showing no sequence homology to any known protein and varying in 
length. This domain is important for the interaction with intracellular proteins and 
mediates the anchoring of the receptor with membrane scaffold proteins and proteins 
that control the signal transmission in the intracellular field. 
 
 
Figure 1. 1: Topology model of the NMDA receptor subunits GluN1 and GluN2. The N-terminal 
domain (NTD, pink) and the ligand binding domain (LBD, orange) including the S1 and S2 
peptide segments are extracellularly located. The three transmembrane domains (blue) 
and the re-entrant P-loop (green) build the ion channel pore followed by the intracellular 
C-terminal domain (CTD, red) (modified from Endele et al, 2010). 
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1.3 Principles of NMDA receptor activation 
Activation of the conventional NMDA receptors requires the presence of two agonists; 
presynaptically released glutamate and extracellular glycine as co-agonist (Johnson 
and Ascher, 1987). Furthermore NMDA receptors are blocked through extracellular 
Mg2+ ions at physiological membrane potential (Mayer et al., 1984; Nowak et al., 1984). 
For the efficient activation of GluN1/GluN2 NMDARs two conditions are required. First, 
membrane depolarization through non-NMDA receptors to release the Mg2+ ion out of 
the pore and second, the binding of glutamate and glycine. Thus, the conventional 
NMDA receptors are called coincidence detectors, linking neurotransmitter activation 
with the electrical state of the neuron.  
Functional and crystallographic studies revealed the molecular structure of ionotropic 
glutamate receptors and lead to a better understanding of the activation mechanism. 
The ligand binding domain is composed of two lobes, S1 and S2, which are arranged in 
a back-to-back-conformation and form a bilobed or clamshell like structure (Furukawa 
and Gouaux, 2003). The agonist binding pocket is located in the interface between the 
two S1 and S2 segments. Agonist binding leads to a clamshell closure and stabilizes a 
closed cleft conformation. This conformational change in the LBD leads to a transition 
to the ion channel followed by separation of the transmembrane domain linkers, which 
finally induce channel opening of the receptor. 
 
 
Figure 1. 2: Structural mechanism of NMDA receptor activation. Both agonists, glycine and 
glutamate, are required for NMDAR channel opening. The agonist binding leads to a 
closure of the LBD, which results in a separation of the transmembrane domain linkers. 
This induces channel opening of the receptor (modified from Paoletti, 2011). 
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1.4 Spatial and temporal expression of NMDA subunits 
The subunit composition and localization of NMDA receptors seem to play an essential 
role for normal brain development. The expression of the NMDA subunits underlies 
different spatial and temporal expression patterns and is developmentally regulated 
(Paoletti, 2011). The obligate GluN1 subunit is ubiquitously expressed in the embryonic 
and adult CNS. Interestingly the expression pattern of the GluN2 subunits depends on 
brain region and developmental stage. The GluN2B subunit is already expressed in the 
embryonic rodent CNS, whereas the GluN2A subunit shows a gradually increase after 
birth. In the adult CNS the expression of the GluN2B subunit becomes restricted to 
forebrain areas, whereas the GluN2A subunit is abundantly expressed in the entire 
brain. The GluN2C subunit appears late in development and the GluN2D subunit is 
expressed already in the early development. The GluN3 subunits show also an unique 
expression profile. The GluN3A subunit reaches maximum expression in the early 
postnatal life followed by a decrease to low levels in adulthood. In contrast the GluN3B 
subunit expression is low in early stages of development with an increase and 
maximum in the adult CNS.  
Furthermore, the subunit composition and cellular localization seem to play a crucial 
role for cell survival and cell death. NMDA receptors are localized at synapses, but also 
extrasynaptically and based on their localization they exhibit different physiological 
roles (Hardingham and Bading, 2003). GluN2A containing NMDA receptors are 
preferentially localized at synapses and promote cell survival. In contrast GluN2B 
containing receptors are extrasynaptically localized and activate pro-death signaling 
pathways.  
Detailed knowledge of the mechanism behind the GluN2A containing receptor induced 
neuroprotection is currently lacking. But it has been demonstrated that calcium influx 
through synaptic GluN2 containing receptors activates two signaling pathways. Both 
activate the cAMP-response-element-binding protein (CREB) through phosphorylation, 
which results in an activation of pro-survival gene and expression of the highly 
protective brain-derived neurotrophic factor (BDNF). Through activation of 
extrasynaptic GluN2B containing receptors the activation is inhibited and CREB gets 
dephosphorylated, which results in a deactivation of CREB. Thus extrasynaptic 
localized GluN2B containing receptors activate a CREB shut-off pathway that block the 
induction of BDNF expression.  
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1.5 Architecture of NMDA receptors 
Structural knowledge of NMDA receptors has been advanced in recent years with 
isolated N-terminal domains and ligand binding domains (Farina et al., 2011; Furukawa 
and Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005; Karakas et al., 2009; 
Karakas et al., 2011). The X-ray structure of the homomeric Glu2A AMPA receptor 
provided a structural template for development of a NMDA receptor model (Sobolevsky 
et al., 2009). But the modes of subunit and domain arrangement of intact 
heterotetrameric NMDA receptors were not elucidated till recently two groups reported 
the crystal structures of the GluN1/GluN2B NMDA receptor. The published crystal 
structures of GluN1/GluN2B NMDA receptors from Karakas and Furukawa and Lee 
and colleagues are the first crystal structures of an NMDA receptor including the NTD, 
LBD and TMD and though give more insight about the architecture, symmetry and 
domain organization of NMDA receptors.  
 
 
Figure 1. 3: Architecture of the GluN1/GluN2B NMDA receptor. Overall structure of NMDA 
receptor complex is shown with GluN1 subunits in blue and the GluN2B subunits in 
orange. The receptor domains are organized in three layers with the NTD, LBD and the 
TMD. (left) View of receptor complex parallel to the membrane and (right) rotated ~ 120° 
around the overall twofold axis (Lee et al., 2014). 
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The overall architecture of the GluN1/GluN2B crystal structures were described as a 
`hot-air ballon` or a `mushroom` with the receptor domains organized into three layers 
with the NTD layer at the top, the LBD layer in the middle and the TMD layer at the 
bottom. Both structures confirmed the GluN1-GluN2-GluN1-GluN2 (1-2-1-2) alternating 
arrangement in the heterotetramer, which was supposed in previous studies (Riou et 
al., 2012; Sobolevsky et al., 2009). The NTDs and LBDs are organized as local 
heterodimers and the extracellular domains are more compact in contrast to the 
homomeric Glu2A AMPA receptor.  
 
 
1.5.1 The role of the N-terminal domain 
An important key feature of NMDA receptors is their capacity for allosteric regulation by 
small molecules such as Zn2+. This allosteric regulation is mediated through the large 
NTDs which form mobile regulatory domains. The overall architecture of the NTDs is 
shaped like a bilobed clamshell composed of the upper lobe (R1) and the lower lobe 
(R2) similar to the bilobed LBD with S1 and S2 lobes. In comparison to Non-NMDA 
receptors the NTDs of the NMDA receptors are substantially twisted. In the full-length 
crystal structure the AMPA receptor subunits are organized as a dimer of dimers where 
the dimer pairs are relatively far apart from each other. In NMDA receptors the NTDs 
also build dimer pairs, like in AMPA receptors, but in contrast the NMDA receptor dimer 
pairs are much more compact (Karakas et al., 2011). This is in concordance with the 
crystal structures from Lee and colleagues (Lee et al., 2014). 
An important allosteric modulator of NMDA receptors is the divalent cation Zn2+. It is 
the most prevalent trace element in the body, which occurres endogenously in the 
brain and has many functional roles (Paoletti et al., 2009). It has been demonstrated 
that Zn2+ is localized in synaptic vesicles at glutamatergic presynaptic terminals 
(Frederickson et al., 2005; Salazar et al., 2005) and the release takes place in an 
activity dependent manner (Smart et al., 2004). Zn2+ can reach concentrations of nearly 
1 µM in the synaptic cleft (Smart et al., 2004).  
Selective inhibition by low micromolar concentration of Zn2+ at NMDA receptors was 
first demonstrated in cultured hippocampal neurons (Perez-Clausell and Danscher, 
1985; Westbrook and Mayer, 1987). Zn2+ acts as an allosteric inhibitor in a voltage-
independent fashion (Choi and Lipton, 1999; Christine and Choi, 1990). Furthermore 
the voltage-independent Zn2+ sensitivity is influenced by the subunit composition.  
 
 8 
 
 
GluN1/GluN2A receptors show high sensitivity in the nanomolar range (Choi and 
Lipton, 1999) whereas GluN1/GluN2B receptors show a 100 fold lower affinity 
(Rachline et al., 2005). The presence of Zn2+ in synaptic vesicles and the abundance of 
potential synaptic targets, especially NMDA receptors, indicate Zn2+ a crucial role as 
modulator of synaptic transmission. 
 
 
1.5.2 The NMDA receptor transmembrane domains and ion channel pore 
The assembly of the different NMDA receptor subunits results in NMDA receptors with 
multiple functions, because the subunit composition determines the functional 
properties of the receptors. Permeation and gating properties of the NMDA receptors 
differ strikingly between the different subunit compositions. GluN2A- and GluN2B-
containing receptors show a higher Ca2+ permeability than GluN2C and GluN2D 
containing receptors (Burnashev N, 1995 ). Furthermore, receptors containing the 
GluN2A or GluN2B subunits show a higher sensitivity to Mg2+ as GluN2C and GluN2D 
containing receptors (Kuner and Schoepfer, 1996; Qian et al., 2005). Structural 
determinants that control the permeation are located in the P-loop within the narrowest 
constriction of the channel pore. In NMDA receptors the narrow constriction is formed 
by the QRN site asparagine and asparagines adjacent to the QRN site (QRN + 1 site) 
in GluN2 (Wollmuth et al., 1998; Wollmuth et al., 1996).  
The recently published crystal structures of a GluN1/GluN2B NMDA receptor reveal 
nearly a complete representation of the ion channel pore and the putative selectivity 
filter (Lee et al., 2014). The pathway through the ion channel pore can be structured 
into three main sections: gate, vestibule and filter. The gate is the first constriction 
located at the extracellular ends of M3, which adopt a pyramid-like shape. This 
represents a physical constriction to the ion channel permeation pathway at the 
extracellular side of the membrane. Residues in the highly conserved SYTANLAAF 
motif define this narrowest constriction, which is implicated in modifying ion channel 
gating properties. Through bundle crossing of the M3 helices at the SYTANLAAF motif 
the ion penetration pathway is occluded.  
The following central vestibule is a cavity flanked by the M3 helices on the side and 
helices with the tips of the pore loop on the bottom. Immediately below the central 
vestibule there is a second constriction of the pore, which builds the selectivity filter. 
This section is defined by residues at the beginning of the pore loop and includes the 
QRN site. Subsequent the pore expands to the cytoplasmic space. 
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Figure 1. 4: Transmembrane domain architecture. (A) View of the ion channel pore with the 
solvent accessible surface along the pore axis. The pore region can be divided into three 
main sections; gate, vestibule and filter. For GluN2B, residues located at the gate, 
vestibule and the filter are shown as yellow spheres. The asparagine 615 is the crucial 
residue at the second constriction of the pore and defines the QRN site. (B) Schematic 
view of the channel pore and the three main sections. (modified from Lee et al., 2014). 
 
 
1.6 Physiological and pathophysiological role of NMDA 
receptors 
NMDA receptors are critical for normal brain function (Dingeldine 1999) and play a 
crucial role in physiological and pathophysiological processes in the CNS. Because of 
the high calcium permeability of NMDA receptors, they play an important role in 
increasing the intracellular Ca2+ concentration. Calcium is a key intracellular signaling 
molecule involved in many types of neuronal plasticity (Malenke and nicoll 1999). But it 
is also a key mediator of excitotoxic cell death if present in excess (Mattson 2003). 
Under physiological conditions NMDA receptors play a crucial role in synaptic plasticity. 
The Ca2+ influx, which is a consequence of receptor activation, contributes to the 
stabilization of the synaptic contacts during the development of the nervous system 
(Nakanishi and Okazawa, 2006). Their dysfunction is implicated in several 
neurodegenerative disorders such as schizophrenia, Alzheimer disease and epilepsy. 
These diseases have been mainly attributed to an overstimulation of the glutamatergic 
transmission. The resulting, excessive Ca2+ influx into the post-synapse, which is 
mostly carried by NMDA receptors, plays a crucial role in neuronal cell death.  
A B 
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In recent years there has been a large amount of research, which advances the 
understanding of the contribution of excitatory glutamatergic transmission to seizures. It 
has been accepted that the overstimulation of glutamatergic transmission and thereby 
the activation of glutamate receptors may be of significant relevance for its clinical 
manifestation (Ghasemi and Schachter, 2011). The involvement of excitatory NMDA 
receptors in the etiology of epilepsy is of main interest in the research of neurological 
disorders because a regulated balance of excitation and inhibition is fundamental for 
proper neurological functions in the CNS. Imbalance in this complex circuit of neuronal 
transmission could lead to neurological disorders and is a hallmark of epilepsy. 
Epilepsy is a disorder of neuronal network excitability and one of the most common 
neurological disorders affecting approximately one percent of the population (Hauser, 
1994). The most prominent characteristics are spontaneously appeared seizures 
caused by synchronized electrical discharges of neurons, which lead to alteration in the 
electroencephalogram (EEG).  
This work presents for the first time that mutations in the NMDA receptor can cause 
variable epilepsy syndromes, which indicates a strong involvement of NMDARs in the 
etiology of epilepsy.  
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1.7 Aim of the study 
Ca2+ permeability and allosteric modulation are fundamental characteristics of NMDA 
receptors. Because of these special features, among ionotropic glutamate receptors, 
NMDA receptors on the one hand trigger neurotoxicity and are involved in different 
neurological disease. On the other hand for this reason they represent promising 
targets for regulation and treatment of various neurological diseases. The functional 
properties of NMDA receptors are strongly influenced by the GluN2 subunit. The aim of 
the project was to investigate the Mg2+ block, the Ca2+ permeability and the allosteric 
modulation of GluN1/GluN2 receptors with epilepsy associated mutations. In 
cooperation with clinical groups we got information about various mutations in GRIN2A 
and GRIN2B, which encode the GluN2A and GluN2B subunits of the NMDA receptor. 
All mutations were detected in patients with different forms of epilepsy. The work 
focused the analysis on mutations in the NTD and the ion channel pore. For this 
purpose we used molecular biology and electrophysiological methods, i.e. site-directed 
mutagenesis and two-electrode-voltage-clamp (TEVC) on Xenopus laevis oocytes. 
This analysis gives us an idea of the involvement of the NTD and the ion channel pore 
on NMDA receptor function in pathological states, especially age-related epilepsy 
syndromes. 
 
For the treatment of neurological disorders like epilepsy, NMDA antagonists are a 
promising tool. Beside allosteric antagonists, glycine site antagonists are under 
investigations for several neurological disorders, also in epilepsy (Jansen and 
Dannhardt, 2003). In clinical trials a main problem with antagonists are the occurrence 
of servere side effects. Due to the use of antagonists in disorder treatment it is 
necessary to investigate the effect and mechanism of antagonists at different receptor 
subtypes. A further objective of this work was the functional characterization of different 
GluN1 antagonist at the excitatory GluN1/GluN3A NMDA receptors. The 
GluN1/GluN3A receptors reveal different features in comparison to conventional NMDA 
receptors and antagonizing of the GluN1 glycine binding site results in enhanced 
receptor activation. This effect would be counteractive in epilepsy treatment. The aim of 
this study was to investigate the potentiation effect, especially the influence of high and 
low affinity GluN1 antagonists on GluN1/GluN3 receptor currents and the effect on 
potentiation strength. 
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2.1 Abstract 
N-methyl-D-aspartate (NMDA) receptors mediate excitatory neurotransmission in the 
mammalian brain. Two glycine-binding NR1 subunits and two glutamate-binding NR2 
subunits each form a highly Ca2+-permeable cation channels which are blocked by 
extracellular Mg2+ in a voltage-dependent manner (Cull-Candy et al., 2001). 
Either GRIN2B or GRIN2A, encoding the NMDA receptor subunits NR2B and NR2A, 
was found to be disrupted by chromosome translocation breakpoints in individuals with 
mental retardation and/or epilepsy. Sequencing of GRIN2B in 468 individuals with 
mental retardation revealed four de novo mutations: a frameshift, a missense and two 
splice site mutations. In another cohort of 127 individuals with idiopathic epilepsy 
and/or mental retardation, we discovered a GRIN2A nonsense mutation in a three-
generation family. In a girl with early-onset epileptic encephalopathy, we identified the 
de novo GRIN2A mutation c.1845C>A predicting the amino acid substitution p.N615K. 
Analysis of NR1/NR2AN615K (NR2A subunit with the p.N615K alteration) receptor 
currents revealed loss of the Mg2+ block and a decrease in Ca2+ permeability. Our 
findings suggest that disturbances in the neuronal electrophysiological balance during 
development result in variable neurological phenotypes depending on which NR2 
subunit of NMDA receptors is affected. 
 
2.2 Paper 
N-methyl-D-aspartate (NMDA) receptors are neurotransmitter-gated ion channels 
involved in regulation of synaptic function in the central nervous system (Cull-Candy et 
al., 2001). The identity of the NR2 subunit (A, B, C, or D) determines many of the 
physiological and pharmacological properties of NMDARs (Cull-Candy and 
Leszkiewicz, 2004). Inappropriate activation of NMDA receptors has been implicated in 
several neurological conditions, such as Alzheimer’s disease and schizophrenia (Lau 
and Zukin, 2007), however, single gene mutations in subunits of the NMDA receptors 
have not yet been reported in Mendelian disorders. Many human disease genes have 
been identified by breakpoint mapping of chromosome rearrangements (Kurotaki et al., 
2002; Najm et al., 2008; Ray et al., 1985; Tonkin et al., 2004). We ascertained two 
male patients with de novo chromosome translocations, 46,XY,t(9;12)(p23;p13.1) and 
46,XY,t(10;12)(q21.1;p13.1), and a common breakpoint in 12p13.1. Subject 1 was 
referred at the age of 2 years because of mild to moderate mental retardation (MR), 
behavioral anomalies, and abnormal electroencephalogram (EEG). Subject 2 was a  
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12-year-old boy with a more complex phenotype including severe mental retardation, 
behavioral and EEG anomalies, and ophthalmological and other manifestations (Table 
2.1). Using serial fluorescence in situ hybridization (FISH) experiments to delineate 
translocation breakpoints, we found both breakpoints in 12p13.1 to disrupt GRIN2B, 
which encode the NR2B subunit of NMDA receptors (Fig. 2.1a,b and Supplementary 
Figs. 2.1 and 2.2). 
In light of the neurodevelopmental phenotype of both translocation subjects with 
translocation, we hypothesized GRIN2B to be the phenocritical gene. In mice, Nr2b is 
required for neuronal pattern formation and synaptic plasticity in general and for 
channel function and formation of dendritic spines in hippocampal pyramidal cells in 
particular (Akashi et al., 2009; Cull-Candy et al., 2001). Transgenic overexpression of 
Grin2b in the forebrain of mice and in the cortex and hippocampus of rats results in 
superior performance in various tests of learning and memory (Tang et al., 1999; Wang 
et al., 2009). Thus, Grin2b seems to represent a rate-limiting genetic factor in gating 
NMDA receptor’s function in the developing and adult mammalian brain strongly 
suggesting involvement of NR2 subunits in human brain function and cognition.  
This assumption was further corroborated by our finding of a third translocation, 
t(16;17)(p13.2;q11.2), disrupting GRIN2A, the gene encoding the NR2A subunit. The 
16;17 translocation was found to co-segregate with epilepsy and variable degree of 
cognitive impairment in a family (Fig. 2.1c-e and Supplementary Fig. 2.3). The index 
subject, referred to as 3-1, was a 26-year-old male with a history of febrile seizures 
followed by tonic-clonic seizures and severe mental retardation. His father (subject 3-
2), paternal aunt (subject 3-3), and cousin (subject 3-4) had a history of grand-mal 
seizures with onset at the end of their first decade that spontaneously decreased 
during adolescence. All four family members had behavioral problems, and subject 3-4 
also had moderate mental retardation (Table 2.2). GRIN2A represented an excellent 
candidate gene based on the crucial role of NMDA receptors in neuronal maturation 
and excitatory synaptic transmission. In addition, submicroscopic deletions in 16p13 
encompassing GRIN2A among other genes have recently been associated with 
intellectual disability and epilepsy (Reutlinger et al., 2010a). 
Grin2a knockout mice show increased spontaneous locomotor activity and 
deficits in contextual fear conditioning and spatial learning, along with reduced 
hippocampal long-term potentiation that is the cellular basis for learning and memory 
(Kiyama et al., 1998; Sakimura et al., 1995). The phenotype of Grin2b-deficient mice is 
more severe as they die perinatally due to severe developmental brain  
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defects (Kutsuwada et al., 1996; Sakimura et al., 1995). These data together with our 
finding of disrupted GRIN2A or GRIN2B in individuls with variable neurodevelopmental 
phenotypes strongly suggest that any disturbance in the number and/or composition of 
NMDA receptors has profound effects on neuronal development and activity in 
humans.  
We further substantiated this hypothesis through detection of point mutations in 
individuals with mental retardation and/or epilepsy. Two cohorts of affected individuals 
were screened for mutations in GRIN2B: the first cohort consisted of 315 individuals 
with mental retardation (185 patients with mild to moderate mental retardation and 130 
with moderate to severe mental retardation) and the second cohort consisted of 153 
individuals (73 with mild to moderate mental retardation and 57 moderate to severe 
mental retardation; and in 23 individuals the severity of mental retardation was 
unspecified). We sequenced the GRIN2A in a third cohort comprising 127 individuals 
with a history of idiopathic epilepsy and/or abnormal EEG and variable degree of 
mental retardation. We identified four individuals with moderate mental retardation and 
behavioral anomalies who had a heterozygous de novo GRIN2B mutation: 
c.411+1G>A in subject 4, c.2044C>T in subject 5, c.2360-2A>G in subject 8, and 
c.803_804delCA in subject 9 (all parental identities were confirmed; Table 2.1 and 
Supplementary Tables 2.1-2.3). The c.2044C>T mutation was absent in 1,080 control 
chromosomes and the other three mutations observed were absent in 360 control 
chromosomes. In silico analysis using splice site prediction programs confirmed that 
c.411+1G>A and c.2360-2A>G disrupt the splice donor and acceptor site, respectively, 
and likely result in altered splicing(Wang and Cooper, 2007) (Supplementary Table 
2.3). Using RNA analysis, we could not detect aberrant GRIN2B transcripts in subject 4 
(c.411+1G>A ) or subject 8 (c.2360-2A>G) (data not shown). However, heterozygosity 
of rs7301328 (c.366C>G) in exon 2 of GRIN2B was only found in genomic DNA 
(gDNA) and not in cDNA of both of these individuals (Fig. 2.2a). This suggests 
monoallelic expression of the wild-type allele due to nonsense-mediated mRNA decay 
of aberrantly spliced GRIN2B transcripts. In contrast, we identified GRIN2B mRNAs 
with a premature stop codon (PTC) in subject 9 carrying the 2-bp deletion 
c.803_804delCA (resulting in p.T268SfsX15), indicating that GRIN2B transcripts with a 
PTC are not efficiently degraded (Fig. 2.2b). The c.2044C>T mutation predicts the 
amino acid substitution p.R682C affecting a highly conserved arginine within the 
glutamate-binding NR2B ligand binding domain (LBD)(Cull-Candy et al., 2001) (Fig. 
2.3a and Supplementary Fig. 2.4a). Our model of the NR2B LBD predicts strong intra- 
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LBD interactions between the guanidinium group of p.R682 with the carboxyl group of 
p.D727 and a backbone carbonyl oxygen of an adjacent helical structure (Fig. 2.3b). 
The p.R682C alteration results in a loss of three hydrogen bonds, thereby destabilizing 
the tertiary structure of the NR2B LBD (Fig. 2.3b, inset), which may affect glutamate 
affinity similar to the substitution of neighboring residues (Laube et al., 2004; Laube et 
al., 1997). However, analysis of agonist dose-response curves revealed no differences 
in affinities of both glutamate and glycine of wild-type NR1/NR2B and mutant 
NR1/NR2BR682C NMDA receptors (Supplementary Fig. 2.5). This data suggests that the 
p.R682C substitution may alter NMDA receptor function through other mechanisms.  
We likewise identified two mutations in GRIN2A (Table 2.1 and Supplementary 
Tables 2.1-2.3): First, we found the heterozygous c.652C>T transition, resulting in a 
premature stop codon (p.Q218X) in a 4-year-old individual (subject 6-1) with mild to 
moderate mental retardation and abnormal EEG. His mother (subject 6-2) and 
maternal grandmother (subject 6-3) also carry the c.652C>T mutation. Both the 
subject`s mother and grandmother had a history of seizures during early childhood 
(Table 2.2). RNA analysis in subject 6-1 revealed monoallelic expression of the wild-
type allele, suggesting that GRIN2A transcripts with the PTC were efficiently degraded 
by nonsense-mediated mRNA decay (Fig. 2.2c). The second mutation we identified 
was the heterozygous de novo c.1845C>A transversion found in a 3-year-old girl 
(subject 7; whose parental identity was confirmed) with early-onset epileptic 
encephalopathy, abnormal EEG, and severe developmental delay (Table 2.2). The 
c.652C>T mutation was absent in 360 control chromosomes and the c.1845C>A 
mutation in 1,080 control chromosomes. The latter change predicts the substitution of 
an evolutionary conserved asparagine for lysine (p.N615K) in the membrane re-entrant 
loop (the P-loop) of the NR2A subunit (Fig. 2.3a and Supplementary Fig. 2.4b), which 
determines the narrow constriction and ion selectivity of the channel (Mayer, 2006). 
Because conversion of the polar residue N615 at the tip of the pore loop to an 
uncharged side chain has been shown to alter inward-current rectification by Mg2+ 
(Wollmuth et al., 1998), p.N615K likely has a strong impact on NMDA channel 
properties (Fig. 2.3c). Indeed, analyzing voltage dependence of NR1/NR2AN615K 
receptor currents revealed loss of the Mg2+ block and decrease in Ca2+ permeability 
(Fig. 2.3d,e). Co-expression of wild-type NR2A and mutant NR2AN615K resulted in 
intermediate effects (Fig. 2.3d), indicating a negative impact of p.N615K on the channel 
properties of heterooligomeric NR1/NR2A/NR2AN615K NMDA receptors.  
Taken together, disruption of GRIN2A in the translocation subjects and the  
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nonsense alteration p.Q218X most likely lead to functional null alleles associated with a 
relatively mild phenotype comprising epilepsy and variable cognitive impairment. 
However, the more severe phenotype in subject 7 with p.N615K can be explained by a 
dominant negative effect on NMDA receptor function.  
The functional properties of NMDA receptors depend on subunit composition, 
with the NR2 subunits controlling channel kinetics and synaptic signalling(Lau and 
Zukin, 2007). The composition of native NMDA receptors undergoes a developmental 
change from heterotetramers containing predominantly NR2B at the early stages of 
development to those containing NR2B, NR2A, or both subunits at mature stage(Cull-
Candy et al., 2001). Regulation of the NR2A:NR2B ratio of synaptic NMDA receptors is 
thought to be a major determinant of the developmental and experience-dependent 
properties of synaptic plasticity (Yashiro and Philpot, 2008). The concept that the 
remodeling of the number and composition of synaptic NMDA receptors is important for 
neuronal activity and development is reflected by the different neurodevelopmental 
phenotypes in individuals with heterozygous GRIN2A and GRIN2B mutations: whereas 
mutations in the prenatally expressed GRIN2B lead to cognitive defects, mutations in 
the postnatally expressed GRIN2A cause epilepsy as the most consistent clinical 
feature. Recently, risk haplotypes of the GRIN1, encoding the NR1 subunit of NMDA 
receptors, have been associated with infantile spasms further indicating an involvement 
of NMDA receptors in epileptogenesis (Ding et al., 2010). The precise 
pathophysiological consequences of the GRIN2A and GRIN2B mutations remain to be 
elucidated. We hypothesize that both loss-of-function mutations causing a change in 
NMDA receptor composition and/or number and missense mutations leading to 
abnormal NR2 subunit function may affect neuronal ion flux and electrical transmission 
between neurons in the human brain. 
 
Accession codes. The cDNA sequence and the genomic reference sequence for the 
GRIN2B gene can be found under accession number NM_ 000834.3 and 
NC_000012.11, respectively. The cDNA sequence and the genomic reference 
sequence for the GRIN2A gene can be found under accession number 
NM_001134407.1 and NC_000016.9, respectively.  
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2.3 Figures 
 
 
Figure 2. 1: Disruption of GRIN2A and GRIN2B in subjects with chromosome translocations and 
different neurodevelopmental phenotypes. (a) Physical map of 12p13.1. BAC (RP11-) and 
fosmid (G248P8) clones used for mapping the breakpoints of subjects with the 9;12 
translocation (subject 1) and the 10;12 translocation (subject 2) are indicated by colored 
bars and the names are given. Red, mapped distal to the translocation breakpoint; green, 
spanned the breakpoint; blue, mapped proximal to the breakpoint. Exons of GRIN2B are 
indicated by vertical bars, exon numbers are given and breakpoint regions are shown. (b) 
FISH with BAC clones RP11-96K24 and RP11-435K13 on metaphase spreads from 
lymphocytes of subjects 1 and 2, respectively, yielded split signals. Wild-type and 
derivative (der) chromosomes are indicated by arrowheads. (c) Physical map of 16p13.2. 
BAC (RP11-) clones used for mapping the breakpoint of subject 3-1 with the 16;17 
translocation are indicated by colored bars and the names are given. Color codes are the 
same as in (a). Exons of GRIN2A are indicated by vertical bars and the exon numbers are 
given. The breakpoint region is indicated. (d) Segregation of the 16;17 translocation in 
members of the family with epilepsy. t(16;17) denotes individuals carrying the 
chromosomal rearrangement, whereas 46,XX and 46,XY denote individuals with normal 
karyotype. The index subject is marked by an arrow. NI, chromosomes not investigated. 
(e) FISH with BAC clone RP11-77E6 on metaphase spread from lymphocytes from 
subject 3-1 yielded split signals. Wild-type and derivative (der) chromosomes are 
indicated by arrowheads. 
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Figure 2. 2: Transcript analysis for the mutations c.411+1G>A, c.2360-2A>G, and 
c.803_804delCA in GRIN2B and c.652C>T in GRIN2A. (a) Partial sequence 
electropherograms of GRIN2B exon 2 obtained from gDNA and cDNA from subjects 4 
(c.411+1G>A) and 8 (c.2360-2A>G) and a healthy individual. Both subjects are 
heterozygous for rs7301328 (c.366C>G) at the gDNA level (upper panel, left and middle). 
In contrast, we observed monoallelic expression of one SNP allele in cDNA of subjects 4 
and 8 (lower panel, left and middle). A control individual showed biallelic expression of the 
SNP alleles in GRIN2B cDNA (lower panel, right). (b) Partial sequence 
electropherograms of GRIN2B exon 3 obtained from gDNA and cDNA of subject 9 
(c.803_804delCA). This subject is heterozygous for the 2-bp deletion in gDNA and cDNA. 
The respective wild-type cDNA sequence from a healthy individual is shown on the right. 
(c) Partial sequence electropherograms of exons 4 and 6 of the GRIN2A obtained from 
gDNA and cDNA of subject 6-1. The subject is heterozygous for both the c.652C>T 
(p.Q218X) nonsense mutation and the rs8049651 (c.1275G>A) at the genomic level 
(upper panel). Sequence analysis of cDNA-derived amplicons revealed monoallelic 
expression (lower panel). 
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Figure 2. 3: Structural and functional consequences of missense mutations in GRIN2B and 
GRIN2A found in subjects with mental retardation and/or epilepsy. (a) Topology model of 
an NR1 and an NR2 subunit.Positions of the two alterations p.R682C and p.N615K are 
indicated by yellow asterisks in the NR2 subunit consisting of an amino-terminal domain 
(NTD), the ligand-binding domain (LBD) including the S1 and S2 peptide segments, three 
transmembrane segments (M1, M2, and M3), a re-entrant pore loop (P), and an 
intracellular carboxy-terminal domain (CTD). Residue R682 in NR2B lies within the 
glutamate binding domain and N615 in NR2A in the ion channel pore. N, NH2-terminus; 
C, COOH-terminus(b) Model of the LBDs of the NR1/NR2B NMDA receptor shows 
residue p.R682 (magenta) within the glutamate-binding NR2B LBD (cyan) together with 
an adjacent glycine-binding NR1 LBD (green). Enlargement shows the loss of the 
stabilizing side chain interactions of p.R682 with p.D727 and the carbonyl oxygen of 
p.G724 upon mutation to cysteine. (c) Transmembrane arrangement of the NMDA 
receptor composed of NR1 (green) and NR2A (cyan) subunits (top view). Enlargement 
highlights the predicted repulsive effect of the positive side chains of p.N615K on cation 
permeability in the pore forming region (side view). (d) Current-voltage (I–V) relationships 
of NR1/NR2A receptors (upper panel). Linear I–V curves of NR1/NR2AN615K (red squares) 
receptor currents reveal a loss in Mg2+-mediated outward rectification of NR1/NR2A (black 
triangles) receptors. Currents of NR1/NR2A, NR1/NR2A/NR2AN615K and NR1/NR2AN615K 
receptors show a gradual loss of voltage-dependent Mg2+ inhibition (lower panel). (e) 
Differences in the reversal potential (indicated by arrows) of NR1/NR2A (black triangles) 
and NR1/NR2AN615K (red squares) receptor currents reveal a decrease in Ca2+ 
permeability of the mutant receptor. 
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Table 2. 1: Clinical data from subjects with mutations in GRIN2B 
 
 
Table 2. 2: Clinical data from subjects with mutations in GRIN2A 
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2.4 Online methods 
Subjects. Detailed information on the patients is found in the Supplementary Note. 
This study was approved by all institutional review boards of the participating 
institutions, and written informed consent was obtained from all participants or their 
legal guardians. 
 
Genome-wide array comparative genomic hybridization (aCGH). Subject 1. We 
obtained genomic DNA from a healthy male 46,XY (G147A, Promega). aCGH was 
performed using commercial Agilent oligo CGH arrays (244K arrays, Agilent 
Technologies) consisting of ~244,000 in situ synthesized 60-mer oligo- nucleotides 
spanning the entire genome, resulting in an average genomic dis- tance of ~12 kb. 
These probes included both coding and non-coding sequences on each human 
chromosome. For hybridization, we digested 3 µg of genomic DNA from the reference 
sample (46,XY) and 3 µg of genomic DNA from subject 1 with AluI (20 units) and RsaI 
(20 units) (Promega). All restrictions were done for a minimum of 2 h at 37 °C then 
heat inactivated at 65 °C for 20 min and verified by agarose gel electrophoresis. 
Labeling reactions were performed with 3 µg of restricted DNA and the Agilent Genomic 
DNA Labeling Kit PLUS (Agilent Techologies) according to the manufacturer’s 
instructions in a total volume of 50 µl with a modified dNTP pool containing dATP, 
dGTP, dCTP and dTTP, and Cy5-dUTP (for subject 1) or Cy3-dUTP (for the 46,XY 
reference). Labeled targets were subsequently filtered twice with ×1 TE-buffer at pH 
8.0 (Promega) through a Centricon YM-30 column (Millipore) and concentrated to 80.5 
µl. The amount and specific activity of the Cy3- and Cy5-labeled samples were 
determined by using the Nanodrop ND-1000 UV-VIS Spectrophotometer (Peqlab) and 
the microarray measurement protocol. The manufacturer’s recom- mendations (Agilent 
Technologies) were followed for selecting or rejecting the probes for hybridization. 
Hybridization and features extraction were performed as described (Barrett et al., 2004; 
Spitz et al., 2006), and data were visualized by means of the CGH Analytics 3.4 
software (Agilent Technologies). 
 
Subject 2. Whole-genome aCGH analysis was performed using a 400K oligo- 
nucleotide array (Agilent) according to protocols provided by the manufacturer. Image 
analysis, normalization and annotation were based on Feature Extraction 9.1 
(Agilent) using the default settings, and visualization of data was performed with the 
CGHPRO software (Chen et al., 2005). 
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Subject 3-1. aCGH was performed using the Human Genome CGH Microarray 244A 
platform (Agilent Technologies). Experimental procedures were performed according 
to the manufacturer’s instructions with slight modifications. One microgram of DNA 
from subject 3-1 and one microgram of reference DNA from a pool of 10 healthy 
donors with a normal male karyotype were hybridized. The array was scanned with 
the Axon GenePix 4000B microarray scanner (Axon Instruments) at a resolution of 5 
µm/pixel. Signal intensities from the generated images were measured and 
evaluated with the Feature Extraction v9.5.3 and CGH Analytics v4.0.81 software 
packages (Agilent Technologies) 
 
Lymphoblastoid cells. Lymphoblastoid cell lines were established according to standard 
protocols and cultured in RPMI medium (Invitrogen) supplemented with 
15% FCS medium, 580 mg/l L-glutamine, 110 mg/l sodium pyruvate, penicillin and 
streptomycin (100 U/ml and 100 µg/ml, respectively) and incubated at 37 °C in a 
humidified atmosphere with 10% CO2. Two hours before preparation of metaphase 
spreads, cells were incubated with 0.2 µg/ml colcemide (Sigma Aldrich) Lymphoblastoid 
cells. Lymphoblastoid cell lines were established according to standard protocols and 
cultured in RPMI medium (Invitrogen) supplemented with 15% FCS medium, 580 mg/l L-
glutamine, 110 mg/l sodium pyruvate, penicillin and streptomycin (100 U/ml and 100 µg/ml, 
respectively) and incubated at 37 °C in a humidified atmosphere with 10% CO2. Two hours 
before preparation of metaphase spreads, cells were incubated with 0.2 µg/ml colcemide 
(Sigma Aldrich). 
 
Fluorescence in situ hybridization (FISH). Metaphase spreads from peripheral blood 
lymphocytes or lymphoblastoid cells were prepared by standard procedures. FISH 
experiments for the delineation of the 9p23, 10q21.1, 12p13.1, 16p13.2 and 
17q11.2 breakpoints were performed with BAC and fosmid clones (Supplementary 
Tables 2.4–2.6). BACs (RPCI-11 libraries 753 and 737) were obtained from ImaGenes 
or from the BACPAC Resources Center (BPRC). Fosmid clones (library WIBR-2) 
were obtained from the BPRC. BAC and fosmid DNA was prepared using the 
NucleoBond Xtra Midi kit (Machery-Nagel). DNA was labeled by nick translation using 
the CGH Nick Translation Kit and Spectrum Green-dUTP or Spectrum Orange-dUTP 
(Vysis) according to the protocols provided. Chromosomes were counterstained 
using 4′,6-diamidino-2-phenylindole (DAPI) (Serva Feinbiochemica) and mounted in 
antifading solution (Vector Labs). Slides were evaluated using an epifluorescence  
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microscope (Leica DMRA) that was fitted with different single band-pass filter sets for 
DAPI, Spectrum Green and Spectrum Orange fluorescence. Images were captured 
using a cooled charged-couple device (CCD) camera (Pieper) and Cyto Vision 
software (Applied Imaging). 
 
Mutation analysis. GRIN2B. Genomic DNA was isolated from blood lym- phocytes 
according to standard procedures. DNA samples from the first cohort of 315 individuals 
with mental retardation and the second cohort of 153 individuals with mental 
retardation were amplified by whole genome amplification using the GenomiPhi V2 DNA 
amplification kit (GE Healthcare). The DNA samples were screened for GRIN2B 
mutations by unidirectional sequencing of all GRIN2B exons (1–13), including flanking 
intronic regions, using the ABI BigDye Terminator Sequencing Kit (Applied 
Biosystems) and an automated capillary sequencer (ABI 3730, Applied Biosystems). 
PCR and sequencing reaction cleanup were performed with the Biomek NXP 
workstation using the Agencourt AMPure PCR purification system and the Agencourt 
CleanSEQ Dye Terminator Removal kit (Beckman-Coulter). Mutations were confirmed 
by independent PCR and bidirectional sequencing using the subjects’ original DNA 
samples. Sequence analysis was done with the Sequencing Analysis v.3.6.1 (Applied 
Biosystems) and the Sequencher 4.9 (Gene Codes Corporation) software packages. 
Primer sequences (Supplementary Table 2.7) were determined using the Exon Primer 
program from the UCSC genome browser (see URLs) and the primers were supplied 
by Thermo Fisher Scientific. 
 
GRIN2A. We analyzed a cohort of 127 individuals with a history of epilepsy, an 
abnormal EEG pattern and a variable degree of mental retardation for GRIN2A 
mutations. We amplified the coding region, including the flanking intronic 
sequences, of GRIN2A (14 exons in total) from genomic DNA. Primer sequences are 
summarized in Supplementary Table 2.8. Amplicons were directly sequenced either 
as described above or using the ABI BigDye Terminator Sequencing Kit (Applied 
Biosystems) and an automated capillary sequencer (ABI 3130, Applied Biosystems). 
Sequence electropherograms were analyzed using Sequence Pilot software (JSI 
medical systems). 
Where mutations were shown to have arisen de novo, we verified self-reported 
relationships by genotyping both parents and the subject at a minimum of fifteen 
microsatellite loci. 
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Computational analyses. Splice site prediction of intronic variants identified in 
GRIN2A and GRIN2B were calculated by using the online tools HSF V2.4 (Desmet et 
al., 2009), SpliceView, the Berkeley Drosophila Genome Project (BDGP) (Reese et al., 
1997) and the NetGene2 server (Hebsgaard et al., 1996). See URLs. 
Prediction of potential deleterious effects of missense mutations detected in GRIN2A 
and GRIN2B was performed using the software tools SIFT (Kumar et al., 2009), 
PolyPhen (Ramensky et al., 2002), SNAP (Bromberg and Rost, 2007) and PANTHER 
7.0 Beta (Thomas et al., 2003). See URLs 
 
GRIN2A and GRIN2B transcript analysis. RNA was isolated from fresh blood 
leukocytes from subjects 4, 6-1, 8 and 9 using the PAXgene Blood RNA System 
(PreAnalytics) according to the manufacturer’s recommendations. First-strand cDNA 
was synthesized from 1–2 µg of RNA using the Omniscript Reverse Transcriptase Kit 
(Qiagen) and gene-specific oligonucleotides. Of a total of 20 µl of volume from the 
reaction, 1 µl was used as template to amplify transcripts by using primer pairs 
spanning different exon-exon junctions in nested PCR reactions. Amplicons were 
directly sequenced or cloned into pCR2.1 TOPO TA Cloning Vector (Invitrogen). 
Escherichia coli clones were subjected to colony PCR, and PCR products from 
individual clones were sequenced. 
 
Molecular modeling of NMDA receptor domains. Sequence alignment of the NMDA 
receptor subunits was taken from a previous study (Sobolevsky et al., 2009) or 
performed using ClustalX 2.0.12 (see URLs). Molecular modeling of the transmembrane 
domains of NR1-NR2A and the LBDs of NR1-NR2B receptors was based on the crystal 
structure of GluR2 (Brookhaven Protein Data Bank entry 3KG2) (Sobolevsky et al., 
2009) and of the NR1-NR2A LBD (PDB ID 2A5T) (Furukawa et al., 2005), respectively, 
by using Modeller 9v6 (Sali lab at the University of California, San Francisco) (Fiser and 
Sali, 2003) and lsqman 9.7.9 (Uppsala Software Factory) (Kleywegt, 1996). Models 
were subjected to short term molecular dynamics simulations using the Charmm27 force 
field, which is implemented in the Tinker 4.2 molecular modeling software (see URLs). 
Figures were made using PyMOL 1.2 (see URLs). 
 
cDNA constructs, oocyte expression and electrophysiology. cDNA constructs 
encoding the mouse NR1-1a, NR2A and NR2B subunits have been described 
previously (Schuler et al., 2008). We introduced mutations with the QuikChange site- 
 
 29 
 
 
directed mutagenesis kit (Stratagene, Agilent Technologies) using mutagenesis primers 
and identified positive clones by DNA sequencing. We obtained and injected 
collagenase-defolliculated Xenopus laevis oocytes (stages 5 or 6) with capped cRNAs as 
described previously (Haeger et al., 2010)). We kept oocytes at 19 °C in sterile frog 
Ringer’s solution (ORi: 90 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 10 
mM HEPES at pH 7.4) supplemented with 50 mg/l gentamy- cin. At 1–3 days after 
cRNA injection, we measured glycine and glutamate dose-response curves in the 
presence of saturating concentrations of the corresponding agonist (10 µM and 100 
µM, respectively) by two-electrode voltage clamping (TEVC) at a holding potential of 
−70 mV as described previously (Haeger et al., 2010). Concentration-response 
curves and current traces shown in the figures were drawn using KaleidaGraph 
(Synergy Software). To monitor the voltage dependence of NR1-NR2A receptor 
combinations, whole-cell current- voltage relationships of saturating glutamate- and 
glycine-induced currents were recorded in 20 mV-intervals ranging from −90 mV to 
+30 mV and nor- malized to the current value obtained at +30 mV above the respective 
reversial potential (Erev). Data points were aligned by using a third order polynomial fit 
(Madry et al., 2010). The relative divalent to monovalent permeability (Pdiv/Pmono) 
was calculated by the Goldman-Hodgkin-Katz constant field (GHK) voltage equation 
assuming no anion permeability as described (Madry et al., 2010). The internal 
concentrations of Na+ and K+ used in the calculations were 20 mM and 150 mM, 
respectively (Madry et al., 2010). Permeability ratios were calculated for each oocyte 
and then averaged. In order to avoid the activation of the oocytes’ native Ca2+-
sensitive chloride currents, all experiments were carried out in oocytes incubated for 
30 min at 20–25 °C with the membrane-permeant Ca2+ chelator 1,2-bis(2-amino- 
phenoxy)ethane-N,N,N′,N′-tetraacetic acid-acetoxymethyl ester (BAPTA- AM, 100 
µM)  before electrophysiological recordings. Mg2+ inhibition (1 mM) was evaluated 
in the presence of 1.8 mM Ca2+ at a holding potential of −70 mV upon application (5 
s) of saturating glycine (10 µM) and glutamate (100 µM) concentrations. 
 
Statistical analyses. Values given represent means ± standard deviation. Statistical 
significance was determined at the P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) levels 
using a Student’s two-tailed unpaired t-test. 
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2.6 Supplementary Information 
 
 
Supplementary Figure 2. 1: Delineation of the translocation breakpoint in 9p23 of patient 1 (see 
also Supplementary Table 4). Chromosome analysis showed a de novo 9;12 translocation 
(karyotype 46,XY,t(9;12)(p23;p13.1)dn). A genome-wide array comparative genomic 
hybridization (aCGH) did not reveal any clinical relevant genomic imbalance. (a) Physical 
map of 9p23. BAC (RP11-) and fosmid (G248P8) clones hybridizing distally and 
proximally to the breakpoint are represented by red and blue bars, respectively. 
Breakpoint spanning BACs are indicated by green bars. The 15-kb breakpoint region is 
represented by a vertical grey bar and flanked by black arrows. Names of clones are 
given. The PTPRD gene is represented by a grey arrow indicating 5’→3’ orientation. (b) 
FISH with BAC clone RP11-794P3 on metaphase spread from lymphocytes of patient 1 
yielded split signals. Wild-type and derivative (der) chromosomes are indicated by arrow 
heads.  
PTPRD encodes the receptor-like protein tyrosine phosphatase (PTP) delta. Human 
receptor-type PTPs play an important role in cancer development and progression as 
somatic mutations of PTPRD have been identified in various cancers (Cox et al., 2005; 
Ostman et al., 2006; Sjoblom et al., 2006; Solomon et al., 2008; Weir et al., 2007). 
Recently, strong evidence has been provided that PTPRD is a human tumor suppressor 
gene (Solomon et al., 2008). However, Ptprd was also found to be involved in 
motoneuron axon targeting (Uetani et al., 2006) and synaptic plasticity (Uetani et al., 
2000)7. Although we can not exclude that disruption of PTPRD in patient 1 contributed to 
his phenotype, interruption of GRIN2B most likely accounts for mental retardation and 
behavioural anomalies in this individual. 
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Supplementary Figure 2. 2: Delineation of the translocation breakpoint in 10q21.1 of patient 2 
(see also Supplementary Table 2.5). He carried a de novo 10;12 translocation 
(46,XY,t(10;12)(q21.1;p13.1)dn). (a) Physical map of 10q21.1. BAC (RP11-) clones 
hybridizing distally and proximally to the breakpoint are represented by red and blue bars, 
respectively, and BAC clones yielding only one signal on chromosome 10 are shown as 
black bars. Genes are represented by grey arrows indicating their 5’→3’ orientation. 
Names of genes and BAC clones are given. The maximum deleted region of ~1.1 Mb is 
indicated in light grey. (b) FISH with BAC clone RP11-666M1 on metaphase spread from 
lymphocytes of patient 2 yielded only one signal on chromosome 10. A genome-wide 
aCGH revealed four additional de novo chromosome 12 deletions larger than 150 kb (see 
below). 
PRKG1 encodes the cyclic guanosine monophosphate-dependent protein kinase I (cGKI). 
To date, haploinsufficiency of this gene has not been associated with a clinical phenotype 
in humans and its function in human brain is presently unknown. In the mouse, Prkg1 
plays an important role in synaptic plasticity and learning (Hofmann et al., 2006). DKK1 is 
an inhibitor of Wnt signalling and counteracts Wnt-mediated effects on bone differentiation 
and adipogenesis. Dkk1 knockout mice are not viable and show morphological defects 
including lack of anterior head structures and abnormalities of limb digits (Mukhopadhyay 
et al., 2001). More recently, it has been shown that Dkk1 contributes to the 
pathophysiology of ischemic neuronal damage (Mastroiacovo et al., 2009). MBL2 is 
presently known to play a role in innate immune defense. Reports from several groups 
indicate that there is a high frequency of dominantly expressed MBL2 alleles resulting in  
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low levels of the corresponding protein in several ethnic groups (Garred, 2008). For 
chromosome 12, four deletions >150 kb were found, one did not harbour a gene (UCSC 
hg 18, 16,875,976-17,078,092), two others which both overlap with published CNVs 
contained genes (ABCC9 and CMAS, 21,980,820-22,161,796, and the 5’ region of some 
SOX5 transcript variants, 24,133,205-24,335,999). The fourth deletion contained the 3’ 
region of all SOX5 transcript variants (23,140,567-23,664,990). Sox5 is expressed in 
neurons, oligodendrocytes, melanocytes, and chondrocytes and plays a role in 
chondrogenesis as well as development of neuronal cell types by controlling the timing of 
critical cell fate and differentiation decisions (Lefebvre, 2010). In summary, we cannot rule 
out that reduced SOX5, PRKG1 and/or DKK1 expression contributes to the clinical 
phenotype of patient 2. Nonetheless, disruption of GRIN2B likely explains his neurological 
symptoms. 
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Supplementary Figure 2. 3: Delineation of the translocation breakpoint in 17q11.2 of patient 3-1 
(see also Supplementary Table 2.6). Chromosome analysis revealed a 16;17 
translocation (t(16;17)(p13.2;q11.2)). Genome-wide aCGH did not show any clinical 
relevant genomic imbalance. (a) Physical map of 17q11.2. BAC (RP11-) clones 
hybridizing distally and proximally to the breakpoint are represented by red and blue bars, 
respectively. The breakpoint spanning BAC RP11-348E14 is indicated by a green bar. 
Names of clones are given. The 100-kb breakpoint region is shown by a black bar. Genes 
are represented by grey arrows indicating their 5’→3’ orientation, and names of genes are 
given. (b) FISH with BAC clone RP11-348E14 on metaphase spread from lymphoblastoid 
cells of patient 3-1 yielded split signals. Wild-type and derivative (der) chromosomes are 
indicated by arrow heads. (i)TMEM97 (transmembrane protein 97) codes for an integral 
membrane protein of unknown function. TMEM97 plays a role in controlling cellular 
cholesterol levels, and its up-regulation has been implicated in the pathogenesis of 
ovarian cancer (Bartz et al., 2009; Wilcox et al., 2007). (ii)The intraflagellar transport 20 
homolog, encoded by IFT20, has been suggested to function in the delivery of ciliary 
membrane proteins from the Golgi apparatus to the cilium (Follit et al., 2006). (iii)TNFAIP1 
[tumor necrosis factor, alpha-induced protein 1 (endothelial)] was identified as a gene 
whose expression can be induced by tumor necrosis factor (TNF) alpha in umbilical vein 
endothelial cells (Wolf et al., 1992). Increased TNFAIP1 transcript levels have been 
detected in brains from patients with Alzheimer’s disease (Link et al., 2003). (iv)POLDIP2 
codes for polymerase (DNA-directed), delta interacting protein 2 which interacts with the 
DNA polymerase delta p50 subunit and inhibits DNA polymerase delta activity by about  
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50% (Klaile et al., 2007; Xie et al., 2005). It also binds to the proliferating cell nuclear 
antigen (Liu et al., 2003). (v)The function of the transmembrane protein 199, encoded by 
TMEM199, is unknown. (vi) SEBOX (SEBOX homeobox) is the human orthologue of 
mouse sebox that is expressed in maturing mouse oocytes, eggs, zygotes, and two-cell 
embryos, in adult mouse brain, skin, ovary, and liver (Cinquanta et al., 2000; Kim et al., 
2008). Homeodomain proteins such as Sebox play a key role in coordinating gene 
expression during development. The human SEBOX protein has substitutions at the 
invariant residues asparagine 51 and arginine 53 suggesting that it may be nonfunctional 
(Cinquanta et al., 2000). (vii)The glycoprotein VTN (vitronectin) is a member of the pexin 
family. VTN is found in serum and tissues and promotes cell adhesion and spreading, 
inhibits the membrane-damaging effect of the terminal cytolytic complement pathway, 
binds to several serpin serine protease inhibitors, and modulates antithrombin III-thrombin 
action in blood coagulation (Felding-Habermann and Cheresh, 1993; Preissner and 
Seiffert, 1998). Altered expression of VTN has been associated with various diseases 
such as cancer, hemorrhagic fever with renal syndrome, and coronary artery disease 
(Ekmekci et al., 2002; Liu et al., 2009; Ryschich et al., 2009). (viii)SARM1 (sterile alpha 
and TIR motif containing 1) is an almost ubiquitously expressed adaptor protein which 
negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling (Carty et 
al., 2006; Nagase et al., 1998). It has been suggested that SARM1 is a candidate gene 
for hereditary infectious/inflammatory diseases (Mink and Csiszar, 2005).(ix) SLC46A1 
(solute carrier family 46 (folate transporter), member 1) codes for a transmembrane 
proton-coupled folate transporter protein that facilitates the movement of folate and 
antifolate substrates across cell membranes in acidic pH environments. This protein is 
expressed in the brain and choroid plexus where it transports folates into the central 
nervous system. It further functions as a transmembrane heme transporter in duodenal 
enterocytes and, potentially, in other tissues like liver and kidney. Its localization to the 
apical membrane or cytoplasm of intestinal cells is modulated by dietary iron levels. 
Mutations in this gene cause the autosomal recessive hereditary folate malabsorption 
(HFM) disease. HFM is characterized by folate deficiency due to reduced intestinal folate 
absorption and subsequent anemia, hypoimmunoglobulinemia, and recurrent infections 
(Qiu et al., 2006). None of the nine genes seems to be a strong phenocritical candidate 
for epilepsy/MR in patient 3-1. 
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Supplementary Table 2. 1: GRIN2A and GRIN2B sequence alterations not annotated in dbSNP 
 
 
 
Supplementary Table 2.1 continued. 
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Supplementary Table 2. 2: In silico protein analysis of amino acid substitutions in GRIN2A and 
GRIN2B. 
 
 
Amino acid substitutions in GRIN2B and GRIN2A were analyzed by the SIFT, PolyPhen, 
PANTHER, and SNAP programs. When the program offered a choice of parameter settings, 
defaults were used. Tolerated, benign, and neutral indicate that the amino acid substitution is 
unlikely to affect protein function. SIFT prediction scores that fall below 0.05 are predicted to 
affect protein function. High values computed by the PolyPhen software indicate that the 
substituted amino acid residue is rarely or never observed in the protein family and therefore 
more likely to affect protein function. PANTHER scores are continuous values from 0 (neutral) to 
about −10 (most likely to be deleterious), and Pdeleterious indicates the probability of functional 
impairment. SNAP accuracy illustrates the likelihood that a prediction for a functional effect of 
an amino acid change is correct. na, not applicable (position does not align to Hidden Markov 
Model). 
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Supplementary Table 2. 3: In silico splice site prediction analysis of sequence alterations in 
GRIN2A and GRIN2B.  
 
 
 
Supplementary Table 2.3 continued 
 
 
 
Splice site prediction for the intronic nucleotide changes in GRIN2B and GRIN2A. Donor and 
acceptor splice site prediction scores were calculated for wild-type and mutated sequences by 
using the computer programs HSF 2.4, SpliceView, NetGene2, and Berkeley Drosophila 
Genome Project (BDGP). High and low scores indicate strong and weak splice sites, 
respectively. Nucleotide changes resulting in loss of splice site are marked by red letters. a, 
silent change; b, this nucleotide change is located in the last exon of the gene; DSS, donor 
splice site; ASS, acceptor splice site. 
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Supplementary Figure 2. 4: Conservation of amino acids R682 in human NR2B and N615 in 
human NR2A. Species, species-specific gene names, protein database accession 
numbers (www.ncbi.nlm.nih.gov/protein) and partial amino acids sequences are given. 
Orthologues residues identical to human NR2B R682 or human NR2A N615 are indicated 
in green letters and nonidentical in red letters. Both amino acid sequence alignments 
demonstrate high evolutionary conservation of R682 in NR2B (a) and N615 in NR2A (b). 
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Supplementary Figure 2. 5: Pharmacological characterization of the apparent glutamate and 
glycine affinities of wild-type NR1/NR2B and mutant NR1/NR2BR682C NMDA receptors. 
Glutamate (left) and glycine (right) dose-response curves of wild-type NR1/NR2B (black 
triangles) and mutant NR1/NR2BR682C (red squares) NMDA receptors were measured 
upon heterologous expression in Xenopus laevis oocytes by two-electrode voltage 
clamping (TEVC). The results revealed similar glutamate concentrations required for a 
half-maximal response (EC50 value) for wild-type NR1/NR2B and mutant NR1/NR2BR682C 
receptors (left panel). Only a slight (2-fold) reduction in the EC50 value for glycine was 
seen for mutant NR1/NR2BR682C NMDA receptors in the presence of saturating 
concentrations of glutamate (right). This indicates no major effect of the substitution 
R682C in the NR2B subunit on apparent agonist affinities of NR1/NR2B NMDA receptors. 
Values present data from 3–6 oocytes for each subunit combination. 
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Supplementary Table 2. 4: FISH data for patient 1 with t(9;12)(p23;p13.1).  
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Supplementary Table 2. 5: FISH data for patient 2 with t(10;12)(q21.1;p13.1).  
 
 
 
Supplementary Table 2. 6: FISH data for patient 3-1 with t(16;17)(p13.2;q11.2).  
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Supplementary Table 2. 7: Primers for mutation analysis of GRIN2B. 
 
 
Supplementary Table 2. 8: Primers for mutation analysis of GRIN2A. 
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Supplementary note regarding human research subjects 
Patients and their parents were clinically assessed by experienced clinical geneticists 
and/or neurologists. Blood samples were collected from patients and parents after 
obtaining informed consent. The study was approved by all Institutional Review Boards 
of the participating institutions. Clinical information pertinent to the diagnosis and, if 
applicable, results from laboratory testing were provided by the parents or legal 
guardians for minors, or by the evaluating authors (Y.H., L.V.M., M.M., U.M., A.Ra., 
S.v.S., I.S., L.V., N.V., D.W., B.Z., M.Z.). The 540 control probands were German 
(white) healthy blood donors as describe elsewhere (Huffmeier et al., 2009)32. 
 
Subjects 
The first cohort for mutational screening of GRIN2B consisted of 315 consecutive 
patients seen either in the clinic of the University Departments of Human Genetics in 
Erlangen or Essen (Germany). 185 had mild to moderate (IQ>50) and 130 moderate to 
severe mental retardation (MR) (IQ<50). 187 were male and 128 female patients. 19 
patients had a positive family history for MR, 296 patients were isolated cases. 60 
patients had seizures, including one patient with absences, two patients with tonic 
clonic seizures, three with febrile convulsions and one with focal seizures. In the 
remaining patients the seizures were not classified in more detail. Standard evaluation 
consisted of detailed clinical investigation, normal chromosome analysis and 
subtelomeric screening, exclusion of fragile-X syndrome and any clinically recognizable 
syndrome. 70% of patients had molecular karyotyping using either Affymetrix 100K, 
250K or 6.0 arrays without any obvious pathogenic aberration. 
The second cohort for mutational screening of GRIN2B consisted of 153 patients 
evaluated at the University Department of Human Genetics in Heidelberg (Germany). 
73 had mild to moderate (IQ>50), 57 moderate to severe MR (IQ<50), and in 23 
patients the severity of MR was not specified. The male to female ratio was 90 to 63, 
including one patient with a positive family history for MR. 35 patients suffered from 
seizures: eight patients had complex focal seizures, another eight patients presented 
with BNS seizures, five patients with focal seizures, six patients with generalized 
seizures, one patient had multifocal seizures, one patient had partial epilepsy, one had 
myoclonic seizures and in five patients the seizures were not further classified. 
Standard evaluation consisted of detailed clinical investigation, normal chromosome 
analysis, exclusion of fragile-X syndrome and any clinically recognizable syndrome. All 
patients had molecular karyotyping using the Affymetrix 6.0 array without any obvious  
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pathogenic aberration. 
The third cohort of patients comprised 127 individuals with a history of epilepsy and/or 
an abnormal EEG pattern, and in most of them a variable degree of MR. These 
patients were evaluated in the clinics of the University Departments of Neuropediatrics 
and Human Genetics in Kiel and Lübeck (Germany), Marseille (France), Liege and 
Antwerp (Belgium). For 99 patients detailed clinical data were available: 51 patients 
had mild to moderate (IQ>50), 44 moderate to severe (IQ<50) MR, and four patients 
had normal intelligence. 50 were males and 49 were females. 25 patients had a 
positive family history for seizures and/or epileptic activity in EEG, 74 patients were 
isolated cases. 40 patients were diagnosed with an epileptic encephalopathy including 
patients with “suppression-burst” pattern, West and/or Lennox-Gastaut syndrome and 
Dravet syndrome or severe idiopathic generalized epilepsy of infancy. In addition, 23 
patients had a focal epilepsy, 27 patients suffered from a generalized epilepsy, four 
from absences and five patients had no obvious seizures but epileptic activity in EEG. 
Previous genetic testing in this cohort included array CGH analysis in 63 patients (all 
negative), SCN1A mutation screening in 13 cases and screening for copy number 
changes in GRIN2A in four patients (Reutlinger et al., 2010a). This cohort was 
analyzed for mutations in the GRIN2A gene (see Mutation analysis, GRIN2A). 
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3.1 Abstract 
Idiopathic focal epilepsy (IFE) with rolandic spikes is the most common childhood 
epilepsy comprising a phenotypic spectrum from rolandic epilepsy (also benign 
epilepsy with centrotemporal spikes, BECTS) to atypical benign partial epilepsy 
(ABPE), Landau-Kleffner syndrome (LKS) and epileptic encephalopathy with 
continuous spike-and-waves during sleep (CSWS) (Berg et al., 2010; Gobbi et al., 
2006). The genetic basis is largely unknown. We detected novel heterozygous 
mutations in GRIN2A in 27/359 patients from two independent cohorts with IFE (7.5%; 
p=4.83x10-18, Fisher’s exact test). Mutations occurred significantly more frequent in the 
more severe phenotypes with mutation detection rates ranging from 12/245 (4.9%) in 
patients with BECTS to 9/51 (17.6%) in patients with CSWS (p=0.009, Cochran 
Armitage test for trend). In addition, exon-disrupting microdeletions were found in 3/286 
patients (1.0%; p=0.004, Fisher’s exact test). These results establish alterations of the 
gene encoding the NMDA-receptor NR2A subunit as a major genetic risk factor for IFE. 
 
3.2 Paper 
Within the spectrum of idiopathic (genetic) focal epilepsy (IFE) with rolandic spikes 
BECTS is characterized by focal and secondarily generalized seizures, which usually 
remit by puberty. The EEG shows rolandic spike and wave discharges (mainly 
centrotemporal spikes, CTS) as the characteristic hallmark(Stephani, 2000). ABPE, 
CSWS and LKS refer to more severe disorders with various seizure types and/or a 
highly pathological (sleep) EEG (Gobbi et al., 2006; Hughes, 2011) as well as 
cognitive, language and behavioral deficits. 
The genetic causes of IFE are largely unknown, although family studies have provided 
evidence for a presumed autosomal dominant inheritance of CTS (Bali et al., 2007; 
Vadlamudi et al., 2006). Linkage studies identified loci for CTS on chromosomes 15q14 
(Neubauer et al., 1998) and 11p13 (Pal et al., 2010). Association of CTS with markers 
in ELP4 has been replicated, but no causative mutation has yet been identified (Strug 
et al., 2009). Following hints from a microdeletion study published by our group that 
GRIN2A, encoding the alpha-2-subunit (NR2A) of the N-methyl-D-aspartate (NMDA)-
selective glutamate receptor, could be an interesting candidate gene in IFE (Reutlinger 
et al., 2010b), we here identify various mutations in GRIN2A in two large independent 
cohorts comprising the whole spectrum of IFEs.  
We first performed a mutation analysis in cohort I (screening cohort) comprising 39  
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patients with IFE and CTS (for all cohorts: Supplementary Table 1). One patient (index 
patient 1, 1/39, 2.6%) with BECTS and learning difficulties was identified carrying a 
novel missense mutation (c.728C>T, p.Ala243Val, family history and segregation 
unknown, parents unavailable) in GRIN2A predicted to be located in the Zn2+-binding 
domain of the glutamate-gated NR2A (Fig. 3.1a,b). Maximal inducible currents, agonist 
affinities and relative open probabilities of mutant NR1-NR2AAla243Val receptors were not 
significantly different upon heterologous expression from those of the respective 
receptors containing the wild-type NR2A subunit (Fig. 3.1c,d). In contrast, currents for 
NR1-NR2A, NR1-NR2A-NR2AAla243Val and NR1-NR2AAla243Val receptors show a gradual 
loss of high-affinity inhibition by 0.1 µM Zn2+ (p<0.01, Fig. 3.1e), suggesting an 
increased activation in vivo due to impaired tonic inhibition of NR1/NR2AAla243Val 
receptors at physiological concentrations of Zn2+. Furthermore, two different mutations 
in GRIN2A were identified by next generation sequencing (NGS) of >300 known and 
suggested epilepsy genes for diagnostic purposes (Lemke et al., 2012) in two patients 
with Landau-Kleffner syndrome not included in cohort I. Index patient 2 carries a novel 
truncating mutation c.2041C>T, p.Arg681* (pedigree shown in Fig. 2), whilst index 
patient 3 has a novel splice site mutation c.1007+1G>A (family history positive, 
segregation unknown, parents unavailable), both predicting non-functional proteins. 
Motivated by these findings and to evaluate the significance of these preliminary 
results, we recruited cohort II (validation cohort) including 119 additional independent 
IFE patients. Sanger sequencing of GRIN2A revealed mutations in 8/119 patients 
(6.7%) that were not listed in dbSNP, 1000Genomes or the Exome Variant Server 
(EVS) databases. Regarding the different sub-entities, mutations were found in 0/3 
patients with isolated CTS, 1/48 patients with BECTS (2.1%), 1/17 patients with ABPE 
(5.9%), 0/17 patients with LKS and 6/34 patients with CSWS (17.6%) (Table 3.1, 
Supplementary Tables 1-3, Supplementary Fig. 1). We finally replicated these findings 
in cohort III (replication cohort) comprising 240 additional patients who underwent 
whole-exome sequencing and subsequent validation by Sanger sequencing. The 
proportion of GRIN2A mutation carriers in the replication cohort was similar to that of 
the validation cohort, with an overall mutation rate of 19/240 (7.9%). Mutations were 
identified in 0/2 patients with isolated CTS, 11/197 patients with BECTS (5.6%), 4/20 
patients with ABPE (10.0%), 1/4 patients with LKS (25.0%) and 3/17 patients with 
CSWS (17.6%) (Table 3.1, Supplementary Tables 1-3, Supplementary Fig. 1).  
We then combined cohorts II and III for subsequent statistical analysis, providing a total 
of 359 patients. Mutations occurred at significantly higher frequency in our patient  
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cohort (27/359; 7.5%) than in the EVS (37/6503; 0.6%) that was used as a reference of 
unaffected controls (p=4.83×10-18, Fisher’s exact test). Restricting the comparison to 
patients and controls of European ancestry yielded similar results (26/315 vs 27/4300, 
p=1.18×10-16, Fisher’s exact test). The frequency of mutation carriers significantly 
increased towards more severe phenotypes (p=0.009; Cochran Armitage test for trend, 
Supplementary Fig. 2). Furthermore, the severity of phenotypes showed substantial 
association with the type of mutation (Pearson’s corrected contingency coefficient 
Ccorr= 0.52; Supplementary Fig. 3). For index patient 2 and 19 cases from cohorts II 
and III, additional family information was available. Of these, two cases were found to 
have different de novo mutations. The remaining 17 cases each exhibited a novel 
mutation that co-segregated with a phenotype of different epileptic disorders (often but 
not exclusively associated with CTS) and various degrees of intellectual disability within 
the family (Fig. 3.2). The GRIN2A locus showed significant linkage to this phenotype in 
these 17 families (two-point parametric LOD score of 3.55 under a dominant risk model 
with reduced penetrance of 80% and complete linkage). 
In addition, 286 IFE patients were screened for copy number variations (CNVs) in 
GRIN2A using the Illumina HumanOmniExpress BeadChip® (Illumina Inc., San Diego, 
CA)  (cohort IV, CNV cohort). This cohort included all patients from cohort III (i.e. an 
overlap of 83.9%) and 46 additional IFE patients. Out of 286 patients, three (1.0%) 
were identified with exon-disrupting microdeletions within GRIN2A (Supplementary Fig. 
4). An additional intronic duplication was found to segregate with the phenotype but 
remains of unknown significance (Supplementary Fig. 4). CNVs of GRIN2A occurred 
significantly more often in patients than in controls (3/286 vs 0/1520, p=0.004). 
Our investigations have revealed mutations as well as exon-disrupting CNVs within 
GRIN2A in a significant subset of IFE patients. We therefore postulate that genetic 
alterations in GRIN2A are not only a major genetic risk factor, but are compatible with a 
monogenetic trait for IFE in up to 7.5% of patients. However, additional modifying 
factors might explain phenotypic variability. Similar to other idiopathic epilepsies 
(Helbig et al., 2009), mutations were occasionally identified in apparently non-affected 
relatives suggesting a mosaic status or incomplete penetrance (although EEG 
abnormalities and rare seizures might have been missed in these individuals). A 
significant trend towards higher mutation rates in more severe phenotypes was 
demonstrated, which is similar to other epilepsy genes such as SCN1A (Claes et al., 
2009; Marini et al., 2007).  
NMDA receptors are tetrameric ligand-gated ion channels, composed of two NR1  
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subunits and two of four NR2 subunits (NR2A-D), which bind glutamate and determine 
the NMDA receptor subtype location as well as functional properties of synaptic 
transmission and plasticity (Paoletti, 2011). Changes in NMDA receptor function have 
been demonstrated in animal models of temporal lobe epilepsy (Di Maio et al., 2012; 
Frasca et al., 2011; Niimura et al., 2005) and the Stargazer mouse model of idiopathic 
absence epilepsy (Lacey et al., 2012). Earlier studies also suggested evidence for a 
role of GRIN2A alterations in individual patients with epilepsy (Endele et al., 2010; 
Lesca et al., 2012; Reutlinger et al., 2010b). NMDA receptors are tonically inhibited by 
Zn2+, a mechanism which has been shown to protect neurons against NMDA receptor 
mediated over-excitation and glutamate toxicity in vitro.  
Functional analysis of the missense mutation p.Ala243Val (index patient 1) 
demonstrated impaired reduction of receptor currents by low concentrations of Zn2+ 
suggesting increased activation of the NR1/NR2A heteromer due to reduced high-
affinity Zn2+-mediated inhibition in vivo. Accordingly, relief of NMDA receptors from 
tonic Zn2+ inhibition results in a higher susceptibility and enhanced Ca2+ influx. This 
mechanism should be particularly effective at synaptically localized NR1/NR2A 
receptors, due to their high-affinity Zn2+-binding site. This finding is in stark contrast to 
the loss of function predicted by truncating mutations, frameshift mutations or deletions 
of GRIN2A (Lesca et al., 2012; Reutlinger et al., 2010). However, different molecular 
alterations of NMDA receptor subunit genes might lead to similar changes in subunit 
composition resulting in comparable changes of electrophysiological properties of the 
receptor (Balu and Coyle, 2011). Moreover, similar phenomena are known from other 
epilepsy-associated genes such as mutations and deletions of SCN1A in Dravet 
syndrome (Marini et al., 2011). 
IFE is characterized by an age-dependent clinical phenotype. NMDA receptor subunit 
composition is also age-dependent with a switch from predominantly NR2B expression 
in early development to more prominent NR2A expression at later stages (Paoletti, 
2011). Therefore, alterations in NR2A may become relevant only in specific age groups 
(Henson et al., 2012). 
In summary, we report genetic alterations in GRIN2A in 7.5% of patients with IFE 
rendering alterations of GRIN2A a major genetic risk factor. This is of particular 
importance as NMDA receptors are promising targets for epilepsy treatment (Ghasemi 
and Schachter, 2011).  
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1000Genomes database (http://www.1000genomes.org/) 
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Figure 3. 1: Structural and functional consequences of missense mutation p.Ala243Val in 
GRIN2A  
Functional analysis of the missense mutation p.Ala243Val (index patient 1) revealed a 
significant reduction of high-affinity Zn2+ inhibition whereas current amplitude, 
glutamate/glycine affinities or relative open probability remained unchanged. (a) Topology 
model of an NR1 and an NR2A subunit. Position of p.Ala243Val is indicated by asterisk in 
the NR2A subunit consisting of an amino-terminal domain (NTD), the ligand-binding 
domain (LBD) including the S1 and S2 peptide segments, three transmembrane 
segments (M1, M2 and M3), a re-entrant pore loop (P) and an intracellular carboxy-
terminal domain (CTD). Residue Ala243 lies within the Zn2+-binding NTD in NR2A. N, 
NH2-terminus; C, COOH-terminus. (b) Model of the NR2A NTD (cyan) together with an 
adjacent NR1 NTD (green). Enlargement shows residue Ala243 within the Zn2+-binding 
NR2A NTD. (c) Pharmacological characterization of the apparent agonist affinities of wild-
type NR1/NR2A and mutant NR1/NR2AAla243Val NMDA receptors. Glutamate and glycine 
dose-response curves of wild-type NR1/NR2A (black triangles) and mutant 
NR1/NR2AAla243Val (red squares) NMDA receptors were measured upon heterologous 
expression in Xenopus laevis oocytes by two-electrode voltage clamping (TEVC; n=5). 
The results revealed similar glutamate and glycine (not shown) concentrations required 
for a half-maximal response (EC50 value; means ± standard deviation) for wild-type and 
mutant receptors. (d) Maximal current responses and kinetics of the open channel blocker 
MK-801 to wild-type NR1/NR2A and mutant NR1/NR2AAla243Val NMDA receptors reveal 
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similar channel activity. Maximal agonist-inducible currents and rate kinetics of MK-801-
mediated inhibition were used for determining the relative open probability (Po) of wild-
type NR1/NR2A vs. mutant NR1/NR2AAla243Val NMDA receptors. (e) Inhibition of agonist-
evoked currents by low concentrations of Zn2+ at wt and mutant NR1/NR2A receptors. 
Currents for NR1-NR2A, NR1-NR2A-NR2AAla243Val and NR1-NR2AAla243Val receptors show 
a gradual loss of high-affinity inhibition by 0.1 µM Zn2+ (n=5; p<0.01; Student’s t-test). 
Traces show currents for NR1-NR2A, NR1-NR2A-NR2AAla243Val and NR1-NR2AAla243Val 
receptors in the absence (black) and presence of 0.1 µM Zn2+ (red traces). 
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Figure 3. 2: Pedigrees of patients with available family information 
Analysis of possible segregation of the respective mutation in family members could be 
performed for index patient 2 and 19/27 mutation carriers of cohorts II and III where DNA 
samples of family members were available. The respective GRIN2A mutation segregated 
with a variable phenotype of seizures, pathologic EEG patterns and/or intellectual 
disability in family members. A few individuals carried the respective familial mutation but 
did not present any clinical features, indicating incomplete penetrance of the mutations or 
mosaicism. However, subclinical phenotypes (e.g. EEG patterns) have not been 
investigated in these individuals. Pedigree 87-4 is suggestive for a phenocopy in the 
proband’s brother. 
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Table 3. 1: Novel mutations detected in GRIN2A 
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3.3 Methods 
Study Design. 
The overall study design is demonstrated in Supplementary Figure 5. Following reports 
on microdeletions including GRIN2A in patients with complex neurodevelopmental 
phenotypes, epilepsy and centrotemporal spikes as a common feature of the EEG 
(Reutlinger et al., 2010b), we started sequencing a small cohort of 39 patients with 
idiopathic focal epilepsies (screening cohort) and identified a first index patient with 
BECTS, learning difficulties and a missense mutation (p.Ala243Val) in GRIN2A. In 
addition, consecutive Next Generation Sequencing (NGS) Epilepsy Panel Analysis for 
diagnostic purposes revealed two additional index patients with LKS and mutations in 
GRIN2A (p.Arg681* and c.1007+1G>A, IVS4, p.?). In these patients, molecular genetic 
analysis of 323 genes that are known to be involved in epilepsy was performed using a 
targeted NGS approach (Epilepsy Panel Version 2) as recently described (Lemke et 
al., 2012). No other patients with mutations in GRIN2A were identified using this 
analysis method to date. 
Motivated by these findings, we analyzed a second cohort (validation cohort) of 119 
patients with idiopathic focal epilepsies and confirmed our findings by analysis of a third 
cohort (replication cohort) of additional 240 patients. For statistical analysis, data from 
cohorts II and III were combined giving a total cohort of 359 patients with idiopathic 
focal epilepsies of childhood and compared to publically available sequence control 
data of the Exome Variant Server (see below). 
In addition to sequence analysis, we performed CNV analysis in a fourth cohort (CNV 
cohort) and compared these data to CNV data from 1520 platform- and ethnicity-
matched in-house controls. 
 
Patients. 
Cohort I (screening cohort) comprised patients with idiopathic focal epilepsies with 
rolandic spikes recruited at the Department of Neuropediatrics at the University 
Hospital Schleswig-Holstein (Kiel, Germany) and the Northern German Epilepsy Center 
for Children and Adolescents (Schwentinental/Raisdorf, Germany).  
For follow-up studies, study cohort II (validation cohort) was recruited by partners at 
European and Argentinian epilepsy centers, children’s hospitals and departments of 
neuropediatrics and neurology.  
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For replication, patients for study cohort III (replication cohort) were recruited by 
collaborating centers of the EuroEPINOMICS-CoGIE (Complex genetics of idiopathic 
epilepsies) initiative (www.euroepinomics.org).  
Cohort IV for CNV analysis (CNV cohort) included all patients of cohort III as well as 
additional patients recruited at the participating centers. 
A summary of cohorts I - IV is given in Supplementary Table 4. 
Phenotyping was performed according to the 2001 and 2010 ILAE classification 
schemes (Berg et al., 2010; Engel, 2001). For analysis, the following epilepsy 
syndromes were used: benign childhood epilepsy with centrotemporal spikes (BECTS, 
also rolandic epilepsy), atypical benign partial epilepsy (ABPE), Landau-Kleffner 
syndrome (LKS) and epileptic encephalopathy with continuous spike-waves during 
sleep (CSWS). Rare forms of benign occipital epilepsy (Panayiotopoulos syndrome, 
Gastaut syndrome) were subsumed under BECTS as these syndromes often show 
overlapping features. Patients who had either BECTS or ABPE and electrical status in 
sleep were subsumed under the phenotype of CSWS as this is a rather atypical feature 
in these epilepsy syndromes and will influence and probably change the clinical 
outcome. In LKS, electrical status in sleep is a frequent symptom of the syndrome. 
Here, CSWS was used synonymously with “electrical status epilepticus in slow wave 
sleep”, ESES (Fernandez et al., 2012). 
All patients and/or their legal guardians gave written informed consent. The study 
protocol was approved at all sequencing centers (Kiel, Tübingen, Cologne, all: 
Germany). Approval for patient recruitment and inclusion in epilepsy genetics studies is 
available at all participating centers. 
 
Control cohorts. 
For statistical analysis of mutation frequencies, control data were derived from the 
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA 
(http://evs.gs.washington.edu/EVS/), release (ESP6500SI), accessed 11/2012). 
Data from CNV analysis were compared to 1520 in-house controls matched for 
analysis platform and geographic origin. This cohort was drawn from the HNR (Heinz 
Nixdorf RECALL) population-based epidemiological study consisting of males and 
females aged 45 to 75 years from an unselected urban population from the Ruhr area 
in Germany (Schmermund et al., 2002). 
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DNA-extraction from blood samples. 
DNA from individual blood samples was extracted locally at the recruitment centers 
using commercially available kits. 
 
Mutation screening and CNV analysis. 
Sequence analysis of cohorts I and II:  
For cohort I and II, mutation analysis of GRIN2A including all coding exons and exon-
intron boundaries was performed using primers given in Supplementary Tables 5a and 
5b. PCR amplification and bidirectional sequencing were done following standard 
protocols(Franke et al., 2008). New and known polymorphisms as well as InDels were 
identified by NovoSNP(Weckx et al., 2005) and Sequence PilotCE (JSI Medical Systems 
GmbH, Kippenheim, Germany). 
Sequence analysis of cohort III:  
Sequence analysis of cohort III was performed using next generation sequencing 
techniques. In brief, DNA was fragmented using sonification technology (Covaris, 
Woburn, MA, USA) and fragments were end repaired and adaptor ligated. SeqCap EZ 
Human Exome Library® v2.0 (Roche NimbleGen, Madison, WI, USA) was used for 
enrichment and samples were analyzed on the Illumina HiSeq 2000® sequencer. Only 
exome data with an average coverage >30x for 85% of the target sequences were 
included in the analysis. Data were filtered using Illumina Realtime Analysis® (RTA) 
software v1.8 and mapped to the human genome reference build hg19 via the 
ELANDv2 alignment algorithm on a multinode compute cluster. PCR duplicates were 
excluded using CASAVA v1.8. Variant calling was performed by SAMtools (version 
0.1.7) for InDel detection. Scripts developed in-house at the Cologne Center for 
Genomics (Cologne, Germany) were applied to detect protein changes, affected splice 
sites, and overlaps with known variants. In particular, variants were filtered for high-
quality unknown variants in GRIN2A compared to an in-house variation database, 
dbSNP build 135 (www.ncbi.nlm.nih.gov/projects/SNP/), 1000Genomes database 
(www.1000genomes.org/) and the Exome Variant Server. 
Pathogenic implications of identified coding variants were assessed by different in silico 
analysis programs (PolyPhen2: www.genetics.bwh.harvard.edu/pph2 and 
MutationTaster www.mutationtaster.org). For intronic SNPs, splice site analysis was 
performed using SpliceView (http://zeus2.itb.cnr.it/~webgene/wwwspliceview_ex.html) 
and HSF2.4 (www.umd.be/HSF). 
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CNV analysis. 
Whole blood DNA was genotyped for 730,525 markers using the Illumina 
HumanOmniExpress BeadChip® (Illumina Inc., San Diego, CA) according to the 
manufacturer’s protocol. Genotypes were analyzed with the Illumina Genome Studio® 
genotyping module (v.2011). CNV calls were generated by using the PennCNV 
software (Wang et al., 2007) by the use of the log R ratio (LRR) and B allele frequency 
(BAF) for all probes included on the genotyping chips. Analysis was restricted to CNVs 
larger than 30kb and coverage of at least five consecutive probes. All potential 
microdeletions were manually inspected for the regional SNP heterozygosity state and 
log2 ratios of the signal intensities to exclude technical artifacts. Subsequently, 
GRIN2A CNV validation of the index patient and CNV segregation in the family was 
conducted by MLPA® (MRC-Holland) and CNV analysis of WES data, respectively.  
 
Statistical analysis. Sequencing studies. 
For statistical analysis of sequencing data, patients from cohorts II and III (i.e. 
validation and replication cohorts) were combined. Due to the small sample size of 
cohort I and isolated index patients 2 and 3, patients of this screening cohort were 
excluded from statistical analysis. 
Fisher’s exact test was used to compare mutation frequencies in cases and EVS 
controls. To exclude potential population stratification effects, an additional analysis 
was performed comparing only patients with European ancestry (geographic origin 
determined by surname and/or self-reported ethnicity; excluding patients from Turkey 
and Russia as these countries cross borders between Europe and Asia and non-
European countries) against the EVS-European-American controls. 
A Cochran Armitage test for trend was used to test the hypothesis of higher mutation 
frequencies in more severe phenotypes and a Pearson’s corrected contingency 
coefficient was calculated to demonstrate an association between the severity of 
phenotypes and the type of mutation. All tests were carried out using the R statistical 
environment v2.15.1 (www.R-project.org).  
Two-point linkage analysis was performed using the LINKAGE package(Lathrop et al., 
1984). We assumed a dominant mode of inheritance with a reduced penetrance of 
80% and complete linkage between GRIN2A and the disease locus.  
CNV studies: 
A Fisher’s exact test was used to compare the frequency of exon-disrupting CNVs in 
cases and in-house controls. 
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Functional studies. 
For Xenopus laevis oocyte experiments, GRIN2A and GRIN1 constructs and capped 
cRNAs were generated as described previously (Endele et al., 2010). Individual stage 
V to VI oocytes were obtained from anaesthetized frogs and isolated by collagenase 
treatment. 10 ng of total GRIN1/2A cRNA were injected into oocytes. Following 
injection, oocytes were kept at 17 °C in ND96 solution (in mM) (96 NaCl, 2 KCl, 1.8 
CaCl2, 1 MgCl2, 5 HEPES, pH 7.4). Glutamate, glycine and Zn2+-dose-response 
curves of wild-type NR1/NR2A and mutant NR1/NR2AAla243Val NMDA receptors were 
analyzed by two-electrode voltage clamp recording. Molecular modeling of the NMDA 
receptor subunits was taken from a previous study (Endele et al., 2010). 
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4.1 Abstract 
Objective: To identify novel epilepsy genes using a panel approach and describe the 
functional consequences of mutations. 
Methods: Using a panel approach, we screened 357 patients comprising a vast 
spectrum of epileptic disorders for defects in genes known to contribute to epilepsy 
and/or intellectual disability (ID). After detection of mutations in a novel epilepsy gene, 
we investigated functional effects in Xenopus laevis oocytes and screened a follow-up 
cohort.  
Results: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the 
NMDA receptor in 2 individuals with West syndrome and severe developmental delay 
as well as 1 individual with ID and focal epilepsy.  
The patient with ID and focal epilepsy had a missense mutation in the extracellular 
glutamate-binding domain (p.Arg540His) whereas both West syndrome patients carried 
missense mutations within the NR2B ion channel-forming re-entrant loop (p.Asn615Ile, 
p.Val618Gly). Subsequent screening of 47 patients with unexplained infantile spasms 
did not reveal additional de novo mutations, but detected a carrier of a novel inherited 
GRIN2B splice site variant in close proximity (c.2011-5_2011-4delTC). 
Mutations p.Asn615Ile and p.Val618Gly cause a significantly reduced Mg2+ block and 
higher Ca2+ permeability leading to a dramatically increased Ca2+ influx, whereas 
p.Arg540His caused less severe disturbance of channel function, corresponding to the 
patient’s milder phenotype. 
Interpretation: We identified GRIN2B gain-of-function mutations as a cause of West 
syndrome with severe developmental delay as well as of ID with childhood-onset focal 
epilepsy. Severely disturbed channel function corresponded to severe phenotypes 
underlining the important role of facilitated NMDA-receptor signaling in epileptogenesis. 
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4.2 Introduction 
Epileptic encephalopathies (EE) constitute a group of disorders in which the epileptic 
activity itself is considered to contribute to severe cognitive impairment or decline 
above and beyond what might be expected from the underlying pathology alone. (Berg 
et al., 2010) West syndrome belongs to this heterogeneous group of disorders 
presenting with distinctive clinical and electrophysiological features usually manifesting 
between 3 and 12 months as clusters of infantile spasms (IS) and a characteristic EEG 
pattern called hypsarrhythmia.(Roger, 2005) The etiology of West syndrome is very 
diverse, and a substantial subgroup is considered to have a genetic origin. West 
syndrome has been associated with mutations in ARX, CDKL5, STXBP1, ST3GAL3 as 
well as various copy number variations (CNVs).(Edvardson et al., 2013; Kalscheuer et 
al., 2003; Paciorkowski et al., 2011; Saitsu et al., 2010; Stromme et al., 2002) 
However, in many cases the genetic defect remains unresolved. 
 
Mutations in GRIN2A and GRIN2B encoding the alpha and beta-2-subunits (NR2A and 
NR2B) of the glutamate-activated N-methyl-D-aspartate (NMDA) receptor are 
associated with several neurodevelopmental disorders. Mutations in GRIN2A have 
recently been detected in idiopathic focal epilepsy with rolandic spikes and related 
epileptic encephalopathies, that is, in Landau-Kleffner syndrome, epilepsy with 
continuous spike-and-waves during slow sleep syndrome and in non-syndromic 
epilepsy associated with ID.(Carvill et al., 2013; Endele et al., 2010; Lemke et al., 
2013b; Lesca et al., 2013) By contrast, GRIN2B has not been described as epilepsy 
gene to date but has repeatedly been considered as a putative candidate gene for 
seizures (Endele et al., 2010; Epi et al., 2013) and mutations were detected in patients 
with ID, autism spectrum disorders (ASD) and schizophrenia.(de Ligt et al., 2012; 
Endele et al., 2010; Freunscht et al., 2013; Kenny et al., 2013; O'Roak et al., 2011; 
O'Roak et al., 2012; Tarabeux et al., 2011) 
 
4.3 Materials and Methods 
We used a targeted massive parallel resequencing approach to diagnostically screen 
357 individuals (Cohort A) with a broad range of epilepsy phenotypes. The panel 
contained 50 known genes comprising EE genes, plus genes for severe ID not 
associated with seizures, but nevertheless suspected to be involved in epileptogenesis 
(e.g. voltage-sensitive and ligand-gated ion-channel genes). Analysis was performed  
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as described previously.(Lemke et al., 2012) Ninety-one of the 357 individuals were 
diagnosed with EE. Detailed clinical information necessary for a more specific epilepsy 
syndrome classification was not available for many of these 91 patients. After detecting 
de novo mutations in GRIN2B within Cohort A, we subsequently screened 47 patients 
with unexplained IS (Cohort B) by conventional methods. Three patients were 
diagnosed with Ohtahara syndrome, 38 with West syndrome, and 6 patients had a 
nonsyndromic early onset EE with IS during the course of the disease. 
 
Sequence analysis 
We performed direct Sanger sequencing to detect point mutations/small indels as well 
as multiplex amplicon quantification (MAQ) to detect CNVs in DNA extracted from 
peripheral blood. All 13 exons and intron-exon boundaries of GRIN2B were analyzed 
by bidirectional sequencing with the BigDye Terminator v3.1 Cycle Sequencing kit on 
an ABI3730 DNA Analyzer (Applied Biosystems, Foster City, CA; primers available 
upon request).  
Additionally, the genomic region containing GRIN2B was screened for CNVs by use of 
an in-house developed technique for MAQ (http://www.multiplicom.com/multiplex-
amplicon-quantification-maq) in Cohort B. This assay comprises a multiplex 
polymerase chain reaction (PCR) amplification of fluorescently labeled target and 
reference amplicons, followed by fragment analysis on the ABI3730 DNA 
Analyzer.(Suls et al., 2006) The comparison of normalized peak areas between the test 
individual and the average of 5 control individuals results in the target amplicon doses 
indicating the copy number of the target amplicon (using the in-house developed 
Multiplex Amplicon Quantification Software ; http://www.multiplicom.com/maq-s). The 
multiplex PCR reaction consists of 10 test amplicons located in the genomic region of 
GRIN2B and 6 reference amplicons randomly located on different chromosomes 
(primer mix is available upon request). 
 
In silico prediction 
Pathogenic implications of identified coding variants were assessed by different in silico 
analysis programs (PolyPhen2, http://www.genetics.bwh.harvard.edu/pph2 and 
MutationTaster, http://www.mutationtaster.org). (Table 4.1) For intronic single 
nucleotide polymorphism, splice site analysis was performed using HSF2.4 
(http://umd.be/HSF/). The mutation of the ligand-binding domain in GRIN2B encoding 
human NR2B was analyzed using the x-ray crystal structure (Furukawa et al., 2005) of  
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rat NR2A (Protein Data Bank # 2A5S). Rat NR2A and human NR2B share 82% 
sequence identity and 88% sequence similarity in their glutamate-binding regions, 
making the rat NR2A structure a useful template for the analysis of mutations in 
GRIN2B. The interactive visualization program University of California, San Francisco 
(UCSF) Chimera(Pettersen et al., 2004) was used for structural analysis. The ‘swapaa’ 
command was used to substitute amino acids, selecting the side-chain from the 
Dunbrack backbone-dependent rotamer library based on lowest number of clashes, 
highest number of hydrogen bonds and highest probability. 
Molecular modelling of the transmembrane domains of NR1/NR2B receptors was 
based on the crystal structure of GluR2 (Brookhaven Protein Data Bank entry 3KG2) 
using Modeller 9v6 (UCSF Sali lab) and lsqman 9.7.9 (Uppsala Software Factory) as 
described.(Furukawa et al., 2005) Models were subjected to short-term molecular 
dynamics simulations using the Charmm27 force field, which is implemented in the 
Tinker 4.2 molecular modelling software (http://dasher.wustl.edu/tinker/). Figures were 
made using PyMOL 1.2 (http://www.pymol.org). 
 
Functional investigations 
For Xenopus laevis oocyte experiments, NR1-1a and NR2B constructs and capped 
cRNAs were generated as described previously.(Endele et al., 2010) Mutations were 
introduced into these constructs using the QuikChange site-directed mutagenesis kit 
(Stratagene, Agilent Technologies, santa Clara, CA) and confirmed by Sanger DNA 
sequencing. Individual stage V to VI oocytes were obtained from anaesthetized frogs 
and isolated by collagenase treatment. 10 ng of total NR1/NR2B cRNA were injected 
into oocytes. Following injection, oocytes were kept at 17 °C in ND96 solution (96 mM 
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4). Glutamate and 
glycine dose-response curves of wild-type NR1/NR2B and mutant NMDA receptors 
were analyzed by 2-electrode voltage-clamp recording as described.(Laube et al., 
1997) Concentration-response curves and current traces shown in the figures were 
drawn using KaleidaGraph (Synergy Software, Reading, PA). To monitor the voltage 
dependence of NR1-NR2B receptor combinations, whole-cell current-voltage 
relationships of saturating glutamate- and glycine-induced currents were recorded in 20 
mV intervals ranging from −90 mV to +30 mV and normalized to the current value 
obtained at +30 mV above the respective reversial potential (Erev) as described 
previously.(Madry et al., 2010) The relative divalent to monovalent permeability was 
calculated by the Goldman-Hodgkin-Katz constant field voltage equation assuming no  
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anion permeability. The internal concentrations of Na+ and K+ used in the calculations 
were 20 mM and 150 mM, respectively.(Madry et al., 2010) Permeability ratios were 
calculated for each oocyte and then averaged. Mg2+ inhibition (1 mM) was evaluated in 
the presence of 1.8 mM Ca2+ at a holding potential of −70 mV upon application (5 s) of 
saturating glycine (10 µM) and glutamate (100 µM) concentrations. 
 
Statistical analyses 
Values given represent means ± standard error of the mean. Statistical significance 
was determined at the p < 0.05, p < 0.01 and p < 0.001 levels using a Student’s 2-
tailed, unpaired t test. 
 
 
4.4 Results 
Sequence analysis and functional investigations 
Among the 357 patients of Cohort A, we identified 2 individuals with West syndrome 
(Patients 1 and 2) carrying novel heterozygous de novo mutations in GRIN2B (2 of 91 
EE cases, 2.2%) affecting key amino acids (p.Val618Gly and p.Asn615Ile) within the 
NR2B ion channel-forming re-entrant loop, as well as a patient with ID and childhood-
onset focal epilepsy (Patient 3) carrying a novel heterozygous de novo mutation 
(p.Arg540His) within the NR2B glutamate-binding domain. (see Table 4.1, Fig 4.1) 
 
Mutation p.Asn615Ile (Patient 2) affects 1 of 2 paired asparagines (Asn615, Asn616 in 
NR2B) in the re-entrant pore-forming loop implicated in Mg2+ block, whilst p.Val618Gly 
(Patient 1) is in close vicinity. Expression of NR1/NR2BAsn615Ile and NR1/NR2BVal618Gly 
heteromers revealed a significant loss of ion-channel block by extracellular Mg2+ and a 
dramatically increased Ca2+ permeability (Fig 4.2), consistent with a gain of function 
and consequent hyperexcitability. By contrast, p.Arg540His (Patient 3) affects a highly 
conserved residue located in the extracellular glutamate-binding region. Mutation of 
p.Arg540His is predicted to abolish the hydrogen bonding with the backbone of Cys746 
and His802, and a cation-pi interaction with His802, possibly leading to a relaxed fold in 
this region. (Fig 3.3) Curiously, rather than affecting glutamate binding, p.Arg540His 
also resulted in a decrease of Mg2+ block and increase of Ca2+ permeability, implying an 
allosteric effect for this mutation. However, the functional impacts were less severe, in 
line with the milder phenotype of the patient. (see Fig 4.2) 
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Among the 47 patients of Cohort B, we detected 1 additional West syndrome patient 
(Patient 4) with a novel paternally inherited heterozygous splice-site variant deleting 2 
base pairs of the splice acceptor site of exon 10, which encodes parts of the ion 
channel pore domain of GRIN2B. In silico prediction suggests a consecutive alternative 
splice acceptor site 6 base pairs downstream of the mutated splice site that is only 
marginally weaker compared to the wild-type splice acceptor site. Use of this 
alternative splice acceptor site is predicted to result in an in-frame deletion of amino 
acids Phe671 and Gln672 (p.Phe671_Gln672del) of the GRIN2B pore complex which 
would be in line with the location of the mutations of the two West syndrome patients 
described above. However, the latter putative splice variation was inherited from the 
patient’s healthy father and no fresh sample or tissue was available to functionally 
confirm the potentially aberrant splicing. Screening for copy number variations by MAQ 
did not reveal additional deletions or duplications affecting GRIN2B in Cohort B.  
 
Patient phenotypes 
Patient 1 was a male born at term after an uneventful pregnancy. Myoclonic jerks and 
infantile spasms occasionally occurring in clusters at the age of 4 months led to the 
diagnosis of West syndrome. At 6 months, old he had no eye contact and presented 
with episodic hyperextension of axial muscels. The result of first EEG was not available 
for review. EEG at age 8 months showed multifocal bursts of irregular spike waves as 
well as rhythmic bilateral generalized spike waves with a frequency of 4 to 5 per 
second reminiscent of modified hypsarrhythmia. During sleep, there was rare irregular 
high-amplitude epileptiform activity with a hypsarrhythmialike pattern. Treatment with 
vigabatrine and pyridoxine led to a slight clinical improvement. Replacement of 
vigabatrine by levetiracetam improved neither seizures (predominantly of myoclonic 
type) nor EEG pattern, whereas implementation of valproate finally led to a significant 
reduction of seizure frequency. At last follow up at age of 2 years and 1 month, the 
boy’s length was at P90, weight at P25 and head circumference at P50. He had severe 
axial hypotonia with episodic hyperextension and could not sit independently. He could 
hold eye contact only briefly before drifting away. At this time, the boy presented 
additionally with dystoniclike movements of his fingers and still no verbal 
communication. 
 
Patient 2 was a female born at term after an uneventful pregnancy. At the age of 7 
weeks she presented with infantile spasms. She held no eye contact and showed  
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muscular hypotonia and showed muscular hypotonia. She had episodic hyperextension 
of axial muscles. These episodes were not recorded on video. Brain magnetic 
resonance imaging (MRI), magnetic resonance spectroscopy, cerebrospinal 
investigation, and metabolic workup were normal. EEG showed typical hypsarrhythmia. 
Treatment with vigabatrine, sulthiame and topiramate failed to decrease seizures, 
whereas implementation of steroid pulse therapy led to an improvement. At last follow-
up at age of 5 years and 3 months, the girl is not able to sit independently. She 
presented with autisticlike behavior and no verbal expression, severe feeding 
difficulties and mild microcephaly. The EEG showed increased theta activity without 
epileptic discharges. The girl still exhibits series of epileptic spasms as well as 
occasional generalized tonic-clonic seizures.  
 
Patient 3 was a female born at 41 weeks after an uneventful pregnancy and conception 
by in vitro fertilization. Early development was delayed, as she sat at 11 months, 
walked at 19 months and used her first words at 18 months. At the age of 3 years, she 
was diagnosed with global developmental delay. There was no evidence for stagnation 
or even regression of development. Since the age of 9 years and 9 months she had 
focal dyscognitive seizures with postictal paresis of the right arm as well as occasional 
bilateral convulsive seizures and status epilepticus. Postictal EEG showed slowing over 
left frontoparietal region, and MRI of the brain showed postictal diffusion restriction in 
the same region that resolved over time. Lumbar puncture and metabolic screening 
were normal. At the last follow up at the age of 10 years and 6 months she had a mild 
intellectual disability and occasional seizures with postictal paresis.  
 
Patient 4 was a male born at term after an uneventful pregnancy. At the age of 2 
months epileptic spasms occurred, which soon evolved into asymmetric tonic seizures. 
EEG at the age of 7 months showed hypsarrhythmia, and multifocal epileptic activity 
was seen at the age of 14 months. MRI of the brain, metabolic workup and lumbar 
puncture were all normal. At last follow up at the age of 4 years, he still had daily 
therapy-resistant tonic seizures and focal motor seizures. He had severe intellectual 
disability with hypotonic muscle tone and was unable to talk or walk. 
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4.5 Discussion 
 
Our investigations revealed de novo GRIN2B missense mutations in 2 of 91 patients 
with unexplained EE (2.2%) and in 1 patient with ID and childhood-onset focal epilepsy. 
We also detected 1 novel inherited putative splice variant in 1 of 47 patients with IS. 
The observation of a possibly reduced penetrance of an inherited splice variant in 
Patient 4 is in agreement with previous observations (Lemke et al., 2013b) in families 
carrying mutations and putative splice variants in GRIN2A. However, much larger data 
sets are needed to prove a role of inherited GRIN2B variants as risk factors for these 
disorders.  
 
Interestingly, the very recent study of the Epi4K consortium revealed 1 additional case 
of a de novo mutation in GRIN2B in 1 of 115 individuals with epileptic encephalopathy 
of Lennox-Gastaut type.(Epi et al., 2013) (see Fig 4.1) The patient shows parallels to 
Patient 3 of our present study. Both mutations p.Arg540His (Patient 3) and 
p.Cys461Phe (Epi4K patient) are located in the extracellular glutamate-binding region 
and both patients present with primary developmental delay and childhood-onset 
epilepsy. 
 
NMDA receptors are tetrameric ligand-gated ion channels permeable to Na+, K+ and 
Ca2+ composed of 2 glycine binding NR1 subunits and 2 glutamate binding NR2 
subunits (NR2A, NR2B, NR2C, NR2D).(Laube et al., 1998; Paoletti et al., 2013) 
Subunit composition of NMDA receptors is spatially and temporally regulated with a 
switch from predominant NR2B expression in early development to more prominent 
synaptically localized NR2A expression at later stages,(Hardingham and Bading, 2010; 
Paoletti, 2011) which might explain the tendency towards earlier-onset epilepsy 
phenotypes in GRIN2B versus GRIN2A mutation carriers.  
 
NMDA receptor subunits are organized into multiple structural domains (see Fig 4.1) 
including a signal peptide, and amino-terminal domain involved in receptor assembly, 
S1 and S2 segments that form the ligand binding domain, 3 membrane-spanning 
domains M1-M3, and a re-entrant pore-forming loop. Lastly, a large intracellular C-
terminus and PDZ domain-binding motif mediate interactions with intracellular proteins 
such as PSD95. In the Exome Variant Server (EVS, National Heart, Lung, and Blood  
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Institute Exome Sequencing Project, http://evs.gs.washington.edu/EVS/), 38 missense  
and no putative essential splice variants are listed in GRIN2B in 6503 healthy controls. 
The described variants are unevenly distributed with the vast majority (27 of 38) of 
variants being positioned within the NR2B C-terminus. Only 9 of 38 variants were 
detected repeatedly, and again 7 of these are within the C-terminus. Curiously, the only 
described de novo aberration within the NR2B C-terminus was detected in an 
apparently healthy control subject(Rauch et al., 2012) whereas all known pathogenic 
GRIN2B mutations causing neurodevelopmental disorders are found within the N-
terminal region, ligand-binding S1 and S2 segments and the re-entrant pore-forming 
loop.(de Ligt et al., 2012; Endele et al., 2010; Freunscht et al., 2013; Kenny et al., 
2013; O'Roak et al., 2011; O'Roak et al., 2012; Tarabeux et al., 2011) (see Fig 4.1) 
This suggests that pathogenic mutations affecting key functional motifs have a greater 
impact on protein function and can negatively influence neurodevelopment and brain 
excitability. This is also reflected by the finding that variants outside the C-terminus of 
GRIN2B occurred significantly more frequently in alleles of EE individuals of Cohorts A 
and B compared to the EVS controls (p=0.0027, Fisher’s exact test). 
 
Interestingly, 2 of the West syndrome patients presented gain-of-function mutations 
(Patient 1, p.Val618Gly and Patient 2, p.Asn615Ile) in the re-entrant pore-forming loop. 
By contrast, Patient 3 with ID, childhood-onset focal epilepsy, and less severe 
developmental delay carried a milder gain-of-function mutation (p.Arg540His), 
positioned in the extracellular glutamate-binding S1 domain. Additionally, in support of 
the hypothesis that epilepsy is caused by gain-of-function mutations in GRIN2B, 
truncating and thus predicted loss-of-function mutations have only been described in 
patients with ID and/or ASD so far.(Kenny et al., 2013) These data suggest a distinct 
genotype-phenotype correlation, although more mutations and functional studies are 
needed to verify this assumption. 
 
In summary, we postulate that genetic alterations in GRIN2B are responsible for ~2% 
(2 of 91) of EE cases, preferentially causing IS and West syndrome. This further 
strengthens the concept that West syndrome comprises a heterogeneous group of 
several disease entities, causing increased brain excitability with a similar and age-
related EEG and seizure pattern. Additionally, our findings reveal further evidence of 
the contribution of altered NMDA receptor signaling to epileptogenesis and establish 
GRIN2B as another key player in epileptic encephalopathies. In the patients described  
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above, the severity of phenotypes corresponds to the electrophysiological severity of 
gain of ion channel function. This is of particular interest as existing NMDA receptor 
blockers such as memantine represent promising drugs to selectively restore the 
altered NMDA receptor function in patients with gain of function mutations in NR2 
subunits, putting NMDA receptors more in focus in the search for new targets in 
epilepsy treatment.(Ghasemi and Schachter, 2011)  
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Table 4. 1: Mutations detected in GRIN2B. 
 
 
 
 
 
Figure 4. 1: Location of GRIN2B mutations in a schematic illustration of the conserved domains 
of the NR2B subunit (SP = signal peptide; ATD = amino terminal domain, involved in 
receptor assembly; S1 and S2 form the ligand-binding domain; Pore = re-entrant pore-
forming and transmembrane spanning domains; PDZ = PDZ domain binding motif). All 
reported de novo mutations and their according phenotypes (ASD = autism spectrum 
disorders, FE = focal epilepsy, ID = intellectual disability, LGS = Lennox-Gastaut 
syndrome, Scz = schizophrenia) are listed in the top row. Mutations causing phenotypes 
without seizures are labeled in black, mutations in epilepsy patients are in red. So far, no 
pathogenic variants have been observed in the C-terminal region of NR2B. Mutations 
causing West syndrome cluster within re-entrant pore-forming domain, whereas the 
mutation causing ID and focal epilepsy was observed in the glutamate-binding domain 
S1, similar to a recently described LGS case. Non-synonymous variants that are believed 
not to be associated with abnormal phenotypes (grey) and are reported more than once 
(in brackets) in the Exome Variant Server (EVS) are listed in the bottom line. 
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Figure 4. 2: Structural and functional consequences of missense mutations in GRIN2B. (a) 
Topology model of an NR1 and an NR2B subunit. Positions of the alterations 
p.Arg540His, p.Asn615Ile and p.Val618Gly are indicated by asterisks in the NR2 subunit 
consisting of an amino-terminal domain (ATD), the ligand-binding domain (LBD) including 
the S1 and S2 peptide segments, 3 transmembrane segments (M1, M2 and M3), a re-
entrant pore loop (P) and an intracellular carboxy-terminal domain (CTD). Residue 
Arg540 lies within the glutamate-binding domain, and Asn615 and Val618 in the ion 
channel pore. N, NH2-terminus; C, COOH-terminus. (b) Model of the transmembrane 
arrangement of the NMDA receptor composed of NR1 (green) and NR2B (cyan) subunits 
(top view). The arrow highlights the side chains of p.Asn615Ile and p.Val618Gly in the 
pore forming region. (c) Gradual loss of Mg2+ inhibition of NR1-NR2B wild-type and NR1-
NR2B mutant receptor currents at -70 mV. Respective sample traces of NR1-NR2B and 
NR1-NR2BAsn615Ile are shown above with inhibition of receptor currents by 1 mM Mg2+ of 
NR1-NR2B (96 ± 0.9 %, n=4) and mutant NR1-NR2BAsn615Ile (14 ± 7.2 %, p<0.0001, n=3), 
NR1-NR2BVal618Gly (48 ± 6.5 %, p=0.0003, n=3) and NR1-NR2BArg540His (81 ± 3.2 %, 
p=0.005, n=5) receptors. (d) Effect on Ca2+ permeability of NR1-NR2B wil-type and NR1-
NR2B mutant receptor currents. Current-voltage (I–V) relationships of NR1-NR2B 
receptors in the absence of Mg2+ in Na+-free extracellular solution reveal significant  
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differences in the reversal potential (indicated by arrows) of NR1-NR2B (-31 ± 1.7 mV, 
n=4, black triangles) and mutant NR1-NR2BAsn615Ile (-1.0 ± 6.8 mV,p=0.004, n=3, red 
squares), NR1-NR2BVal618Gly (-5.4 ± 3.7 mV, p<0.001, n=3, green squares) and NR1-
NR2BArg540His (-9.4 ± 6.5 mV, p=0.013, n=3, blue squares) receptor currents. (NMDG-Cl, 
N-methyl-D-glucamine chloride) Calculation of the relative divalent to monovalent cation 
permeability PCa/PNa by the Goldman-Hodgkin-Katz voltage equation revealed a >3-fold 
increase in Ca2+ permeability of the mutant NMDA receptors (PCa/PNa for NR1-NR2B: 
0.86, NR1-NR2BAsn615Ile: 5.22, NR2BVal618Gly: 3.12 and NR2BArg540His: 3.23). 
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Figure 4. 3: Structural and functional analyses of the glutamate binding-domain mutation 
Arg540His. (a) Residue 540 is predicted to be located within the glutamate-binding S1 
domain, and is significant in the stabilization of the tertiary structure of the glutamate 
binding-domain. (b) Substitution p.Arg540His is likely to abolish hydrogen bonding (blue 
lines) with the backbone of Cys746 and His802 and a cation-pi interaction with His802, 
possibly leading to a relaxed fold in this region. (c) Pharmacological characterization of 
the apparent agonist affinities of wild-type NR1-NR2B (black triangles) and mutant NR1-
NR2BArg540His (red squares) NMDA receptors measured after heterologous expression in 
Xenopus laevis oocytes by two-electrode voltage-clamping revealed similar glutamate 
concentrations were required to elicit half-maximal response (EC50-value 0.72 ± 0.22 µM 
and 0.31 ± 0.02 µM, p=0.14, n=3, respectively). (d) Arg540 is a highly conserved residue 
within NR2A-D subunits. 
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5.1 Abstract 
N-methyl-D-aspartate (NMDA) receptors belong to the family of ionotropic glutamate 
receptors, which mediate most excitatory synaptic transmission in the mammalian 
brain. They are tetrameric cation channels composed of two glycine-binding GluN1or 
GluN3A subunits and two glutamate-binding GluN2 subunits. For efficient activation 
conventional GluN1/GluN2 NMDA receptors require both agonists, glutamate and 
glycine. In contrast recombinant receptors composed of two GluN1 and two glycine 
binding GluN3 subunits lack glutamate binding sites and can be activated by glycine 
alone. These so called “excitatory glycine receptors” showed a potentiation of receptor 
currents upon coapplication of GluN1 antagonists. The potentiation effect of 
GluN1/GluN3A receptors is still an open question. For further investigation, which 
determinants are important for this effect we analyzed several GluN1 antagonists in 
terms of potentiation strength. Two electrode voltage clamp recordings from 
GluN1/GluN3A expressing oocytes were measured upon co-application with low and 
high affinity GluN1 antagonists. The results showed a relationship between the affinity 
of GluN1 glycine site antagonists and the potentiation efficacy. Low affinity GluN1 
antagonists result in a slide potentiation, whereas high affinity GluN1 antagonists 
reveal a strong increase of receptor currents. In summary all tested GluN1 antagonists 
turned out to be positive modulators of GluN1/GluN3A receptors and our results 
present strong evidence for a correlation between the affinity of the GluN1 antagonists 
and the potentiation strength.  
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5.2 Introduction 
NMDA receptors are ligand gated ion channels that mediate excitatory 
neurotransmission in the brain. They are heterotetrameric membrane proteins 
comprised of the glycine-binding GluN1 and GluN3 subunits or the glutamate-binding 
GluN2 subunit. Each subunit shares a common modular structure characterized by the 
extracellular N-terminal domain (NTD), the ligand binding domain (LBD), three 
transmembrane domains (TMDs) plus an intracellular P-loop forming the ion channel 
pore, and an intracellular C-term domain (CTD) (Traynelis et al., 2010). Agonist 
recognition occurs in the ligand binding domain, which is composed of the two domains 
S1 and S2 (Furukawa and Gouaux, 2003; Laube et al., 1997). Agonist binding results 
in a clamshell closure. This ligand-induced movement of the LBD impacts the linker 
region, which is connected to the transmembrane domains and leads to channel 
opening. 
The so called “conventional” NMDA receptors are composed of two GluN1 and two 
GluN2 subunits and need two agonists for efficient channel opening: glycine and 
glutamate, and the relief of Mg2+ ion out of the channel pore (Traynelis et al., 2010). 
The GluN3 subunits are the last detected members of the NMDA receptor gene family 
(Ciabarra et al., 1995; Nishi et al., 2001; Sucher et al., 1995). Assembly of GluN1 and 
GluN3 subunits results in tetrameric receptors, which were exclusively activated by 
glycine (Awobuluyi et al., 2007; Chatterton et al., 2002; Madry et al., 2007). In contrast 
to the conventional NMDA receptors GluN1/GluN3A receptors display a different 
pharmacological profile. Activation of GluN1/GluN3A receptors with glycine leads only 
to small and rapid desensitized currents and they are insensitive for Mg2+ (Chatterton et 
al., 2002) Functional studies revealed structural and pharmacological differences 
between GluN1 and GluN3, because of strikingly different binding affinities of agonists 
and antagonist. Yao and Mayer showed that soluble ligand binding domains from 
GluN3A subunits bind glycine with a 650 fold higher affinity than GluN1 subunits (Yao 
and Mayer, 2006). Furthermore, they revealed that glycine site antagonists e.g. 5,7-
dichlorokynurenic acid exhibits strong selectivity for binding the GluN1 versus the 
GluN3A subunit (Yao and Mayer, 2006). 
Concerning GluN1/GluN3 receptors, glycine seems to have a dual action at the GluN1 
and GluN3 subunits with regards to the activation mechanism because it acts 
agonistically at the GluN3 subunit and inhibitory at the GluN1 subunit (Awobuluyi et al., 
2007; Madry et al., 2007). Interestingly antagonizing the GluN1 subunit of GluN1/GluN3 
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receptors results in a potentiation of receptor currents (Madry et al., 2007). 
Coapplication of the high affinity GluN1 antagonist MDL ((E)-4,6-Dichloro-3-(2-phenyl-
2-carboxyethenyl)indole-2-carboxylic acid (Baron et al., 1992) together with the agonist 
glycine, results in a 25 fold potentiation of receptor currents (Madry et al., 2007). 
Furthermore, introducing a mutation in the GluN1 LBD, which was shown to nearly 
abolish the glycine affinity of the GluN1 subunit, results in an enhancement of receptor 
currents, without coapplication of the antagonist MDL (Madry et al., 2007). Madry and 
colleagues proposed a model for the activation mechanism of GluN1/GluN3 receptors: 
glycine binding to the GluN3 subunit leads to a conformational change in the LBD and 
induces a closure of the clamshell. Binding of glycine to the low affinity GluN1 LBD 
weakens the interdomain interactions between the GluN3 and GluN1 LBDs, which 
results in receptor desensitization. Crystallographic studies of the soluble LBD revealed 
that antagonist binding stabilizes the binding domain clamshell in an open conformation 
(Furukawa and Gouaux, 2003). Antagonizing the GluN1 ligand binding pocket seems 
to affect the structure of the clamshell and lead to an open clamshell structure. This 
results in an potentiation of the small and rapid desensitizing glycine currents.  
Because the determinants of the potentiation effect are not yet known, in the present 
study we investigated several GluN1-glycine site antagonists at GluN1/GluN3 
receptors. We examined high and low affinity GluN1 antagonists and their effect on 
potentiation strength at GluN1/GluN3A receptors. The results showed an increase of 
efficacy of the GluN1/GluN3A receptor currents upon antagonizing the GluN1 LBD in 
different magnitude in correlation with the affinity of selected antagonist. 
 
 
 
5.3 Methods 
DNA Constructs and cRNA Synthesis 
cDNAs encoding the GluN1-1a (Genbank accession no.U11418) were provided by Dr. 
S. Heinemann (Salk Institute , La Jolla, CA, USA) and GluN3A-1 (Genbank accession 
no. U29873) provided by Dr. D. Zhang (Stanford-Burnham Medical Research Institute, 
La jolla, CA, USA). For expression the cDNAs were linearized with restriction enzyme 
NotI and were used as a template for cRNA synthesis using sp6 mMessage mMachine 
kit (Ambion Life Technologies,Paisley,UK).  
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Xenopus Oocyte Preparation and Expression 
For isolation of oocytes female Xenopus laevis frogs were anesthetized with 0,1 % 
tricain and the oocytes were transferred to ND96 solution [96 mM NaCl, 2 mM KCl, 1 
mM CaCl, 1 mM MgCl2 and 5 mM HEPES (pH 7.4)]. Individual oocytes were 
defolliculated by 2 h incubation in type IIA collagenase. After collagenase treatment the 
oocytes were washed with Ca2+-free ND96 and stored in ND96 solution. 
For heterologous expression of GluN1/GluN3A receptors, 25 ng of GluN1 and GluN3A 
cRNA was coinjected in selected stage V-VI oocytes and maintained at 18 °C in ND96 
solution supplemented with 100 µg/ml gentamycin. 
 
Two-Electrode Voltage-Clamp Recordings 
Two-electrode voltage-clamp (TEVC) recordings were performed on Xenopus oocytes 
at room temperature 3-4 days after cRNA injection. Current responses were measured 
under continuous perfusion with Ca2+-free frog ringer solution (pH 7,4). The 
microelectrodes used for voltage clamping were filled with 3 M KCl solution. For 
recordings the oocytes were clamped at -70 mV and currents were amplified with a 
Geneclamp 500B amplifier, digitized with Digidata 1322A interface and recorded with 
Clampex version 10.2 (Molecular Devices, Sunnyvale, CA).  
 
GluN1 Antagonists 
The GluN1 antagonists used in the experiments were purchased from Tocris 
Bioscience (Bristol, United Kingdom). Stock solutions were solved in DMSO or sigma 
water. Agonist and antagonist dilutions were made in frog ringer solutions. The used 
antagonists are: HA-966 (1-Hydroxy-3-aminopyrrolid-2-one) (Fletcher and Lodge, 
1988; Foster and Kemp, 1989); Cycloleucine (1-Amino-1-cyclopentanecarboxylic acid) 
(Snell and Johnson, 1988) ;Kynurenic acid (4-Hydroxyquinoline-2-carboxylic acid) 
(Stone and Burton, 1988); 7-CKA (7-Chloro-4-hydroxyquinoline-2-carboxylic acid) 
(Kemp et al., 1988) ; 5,7-DCKA (5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid) 
(Baron et al., 1990) ; MDL (2-Carboxy-4,6-dichloro-1H-indole-3-propionic acid) (Baron 
et al., 1992);  L-689560 (trans-2-Carboxy-5,7-dichloro-4-phenylaminocarbonylamino-
1,2,3,4-tetrahydroquinoline) (Leeson et al., 1992) 
 
Statistical analysis  
Values given represent means ± standard error of the mean. Statistical significance 
was determined at the P < 0,05 (*), P < 0,01 (**) and P < 0,001 (***) 
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5.4 Results 
GluN1/GluN3 receptors are activated solely through glycine but generate only small 
currents upon agonist application. Antagonizing the GluN1 subunit leads to a 
potentiation of receptor currents. The high affinity GluN1 antagonist MDL is known to 
potentiate GluN1/GluN3A receptor currents upon coapplication with glycine (Madry et 
al., 2010; Madry et al., 2007). Because of the fact that the mechanism of this 
potentiation is not clear, we characterize further GluN1 antagonists at GluN1/GluN3A 
receptors. Figure 5.1 shows the structure of the GluN1 antagonists, analyzed in the 
present study. The selected antagonists have different affinities for the GluN1 subunit 
covering a broad spectrum from the milimolar to the nanomolar range. MDL, DCKA, 7-
CKA and L-689560 are high affinity glycine site antagonists, whereas HA-966 and 
Cycloleucine, Kynurenic acid are weak antagonists. All selected GluN1 antagonists 
bind with higher affinity to the GluN1 than to the GluN3A subunit (Yao and Mayer, 
2006).  
 
To investigate the effects of the GluN1 antagonists on GluN1/GluN3A receptor currents 
we coapplicated the antagonists with saturating glycine concentration. Receptor 
currents were increased upon adding the antagonists (Fig. 5.2A) and showed a 
potentiation in different extent in dependence of the antagonist (Fig. 5.2B). The 
antagonist HA-966 revealed a slight increase of receptor currents after coapllication 
with glycine, which led to a 1.6 fold potentiation. Coapplication of the antagonists 
Cycloleucine and Kynurenic acid showed also a slight, but in comparsion with HA-966 
a stronger potentiation. Cycloleucine led to a 2.84 fold potentiation, whereas the 
kynurenic acid coapplication resulted in a significant 4.49 fold potentiation. The high 
affinity glycine site antagonists 5,7-DCKA ,7-CKA, MDL and L-689560 showed a strong 
potentiation. Coaplication of 5,7-DCKA with glycine resulted in 23.45 fold potentiation, 
whereas the 7-CKA led to a 30.6 fold increase of receptor currents. Maximal 
potentiation was seen with the antagonists MDL (63.6 ±14.0) and L-689560 (73.4 ± 
19.4). In summary all measured GluN1 antagonists resulted in a significant increase of 
receptor currents. 
 
Because we used GluN1 antagonists with different affinities the next step was to verify 
the affinity of the GluN1 antagonists at the heterologoues expressed GluN1/GluN3 
receptors. Therefore we measured the apparent affinity of GluN1 antagonist. The EC50 
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values were determined in the presence of 10 mM glycine (Table 5.1). The results 
confirmed the different affinities of the GluN1 antagonists with the low affinity 
antagonists Cycloleucine, HA-966 and Kynurenic acid with EC50 values in the mM to 
µM range and the high affinity antagonists with EC50 values in the lower µM to nM 
range. The EC50 values are nearly in the range of the Kd values determined at the 
soluble GluN1 S1S2 (Yao and Mayer, 2006).  
 
Previously, the GluN1 antagonist MDL has been shown to accompany by an increase 
of the apparent glycine affinity during coapplication (Madry et al., 2007). Therefore the 
pharmacological characterization of the apparent glycine affinity were analyzed in the 
presence of constant GluN1 antagonist concentrations and increasing glycine 
concentrations. The dose response curves showed an increase in the EC50 values of 
glycine in the presence of the antagonists, except HA-966 (Fig. 5.3). The coapplication 
of HA-966 showed no significant increase of the glycine EC50 (12.29 ± 4.1 µM) in 
comparison with the glycine EC50 without antagonist (8.49 ± 0,89 µM). The 
coapplication of the GluN1 antagonist Cycloleucine showed a slight but significant 
increase of 30 ± 3.7 µM. With Kynurenic acid coapplication the EC50 value of glycine 
incrases significantly to 742 ± 222 µM. Also a strong and significant shift of the 
apparent affinity revealed due to the coapplication of the high affinity GluN1 
antagonists MDL (1.05 ± 0.38 mM), 7-CKA (1.34 ± 0.16 mM) and 5,7-DCKA (2.19 ± 
0.11 mM). The maximal shift in the apparent affinity was shown with the high affinity 
GluN1 antagonist L-689560 (2.42 ± 0.58 mM). The apparent affinities with the high 
affinity antagonists are in a similar range and differ not significantly among each other. 
 
The potentiation effect seems to be dependend on the GluN1 antagonist affinity. 
Because of this observation, we try to correlate the x-fold potentiation with the obtained 
GluN1 antagonist apparent affinity and also with the Kd values from the soluble GluN1 
S1S2 (Fig. 5.4 A+B). Interestingly there is a correlation between the affinity of the 
GluN1 antagonist and potentiation strength. Increasing affinity of GluN1 antagonists 
results in an increase of receptor currents. In the case of the EC50 values for glycine in 
presence of constant GluN1 antagonist concentrations there is no obvious correlation 
(Fig. 5.4 C). Between the obtained apparent affinities in the heterologoues expression 
system and the affinities from the soluble GluN1 S1S2 domain, we could obtain a clear 
linear correlation (Fig 5.4 D). 
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In summary all selected GluN1 antagonists were positive modulators of GluN1/GluN3A 
receptor currents and coapplication with the agonist glycine resulted in a potentiation. 
This potentiation effect can be correlated with the affinity of the GluN1 antagonists. 
Weak GluN1 antagonist affinity resulted in a slight potentiation, whereas high affinity 
GluN1 antagonists resulted in a strong potentiation. 
 
 
 
5.5 Figures 
 
 
Figure 5. 1: Chemical structure of GluN1 antagonists. The selected GluN1 antagonists are 
competitive to the GluN1 glycine binding site and exhibit different affinities for the glycine 
binding site of the NMDA receptor. HA-966 is a low-efficacy partial agonist/antagonist of 
the glycine site with a Kd value of 162.58 µM (Miyazaki et al., 1999). The weak GluN1 
antagonist Cycloleucine revealed an affinity for the glycine binding site with a Kd of 15.3 
mM (Inanobe et al., 2005). The antagonists Kynurenic acid, 7-CKA , 5,7-DCKA, L-689560 
and MDL revealed affinities with Kd values of 53 µM, 2,6 µM, 0,54 µM, 29,3 nM and 3,89 
nM (Miyazaki et al., 1999; Yao and Mayer, 2006). 
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Figure 5. 2: Effects of GluN1 antagonists on GluN1GluN3A receptor currents. (A) Glycine 
induced currents were increased upon adding GluN1 antagonists. Sample traces at -70 
mV were activated with saturating glycine concentration (10 mM) in absence and 
presence of GluN1 antagonists. Control represent the application with glycine alone. 
Glycine and GluN1 antagonist application is indicated as black bars. (B) Relative 
potentiation by GluN1 antagonists of GluN1/GluN3A receptor currents at -70 mV: HA-966: 
1.6 ± 0.1 (n=10); Cycloleucine: 2.84 ± 0.2 (n=9); kynurenic acid: 4.49 ± 1,2 (n=8); 5,7-
DCKA: 23.45 ± 2.4 (n=13); 7-CKA: 30.6 ± 6.4 (n=8); MDL: 63.6 ± 14.07 (n=7); L-689560: 
73.4 ± 19,4 (n=7). Error bars indicate SEM. 
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Figure 5. 3: Pharmacological characterization of the apparent glycine affinity upon GluN1 
antagonist application. Coapplication of GluN1 antagonists result in a shift of the apparent 
glycine affinity. Wt (dashed line ): 8.49 ± 0.89 µM (n=7); HA-966 (): 12.29 ± 4.1 µM 
(n=6); Cycloleucine (▲): 30 ± 3.7 µM (n=4); Kynurenic acid (▼): 742 ± 222 µM (n=7); 
MDL (): 1.05 ± 0.38 mM (3); 5,7-DCKA (): 2.19 ± 0.11 mM (n=13); 7-CKA (): 1.34 ± 
0.16 mM (n=8); L-689560 (): 2.42 ± 0.58 mM (n=3)  
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Figure 5. 4: Correlation of different parameters with the x-fold potentiation. The x-fold 
potentiation increased with higher affinity of the GluN1 antagonists. (A) Kd values 
obtained from the soluble GluN1 S1S2 in correlation with the x-fold potentiation (B) EC50 
values of GluN1 antagonists measured during coapplication with saturating glycine in 
correlation with the x-fold potentiation. (C) EC50 values of glycine in presence of GluN1 
antagonists. Low affinity GluN1 antagonists HA-966 and Cycloleucine showed no or only 
a slight reduction in the apparent affinity. The high affinity antagonists result in an 
increased EC50 value, thus in a strong reduction of apparent glycine affinity, but without 
obvious correlation between the x-fold potentiation and the altered apparent affinity of 
glycine. (D) Linear correlation between the obtained EC50 values of the GluN1 antagonists 
and the KD values from the soluble GluN1 S1S2. 
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Table 5. 1: Apparent affinity of GluN1 antagonists at GluN1/GluN3A receptors. GluN1 
antagonists EC50 values were determined in the presence of 10 mM glycine (except HA-
966, in presence of 100 µM glycine) 3-4 days after injection of GluN1 and GluN3A subunit 
cRNA. Values represent means ± SEM, n number of experiments. 
 
GluN1 antagonist EC50  n 
   HA-966 414 ± 144  µM 3 
Cycloleucine 11814 ± 871  µM 7 
Kynurenic acid 220 ± 69 µM 4 
5,7-DCKA 1.58 ± 0.87 µM 4 
7-CKA 3,2 ± 1.6 µM 7 
MDL 0.098 ± 0.01 µM 3 
L-689560 
 
0.78 ± 0.05 µM 
 
5 
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5.6 Discussion 
In this study we investigated several GluN1 antagonists at GluN1/GluN3A receptors 
and their potentiation effect on receptor currents. Madry and colleagues already 
showed a potentiation effect with the high affinity GluN1 antagonist MDL. The 
mechanism of potentiation of the small, rapid desensitized glycine induced currents 
through GluN1 antagonists is still unclear. For further investigation which determinants 
are important for this effect we analyzed different GluN1 antagonists, which exhibit 
different ligand affinities for the soluble GluN1 S1S2 LBD. 
 
Crystallographic and functional studies showed that agonist activity is associated with 
binding within the LBD clamshell cleft that stabilizes the closed conformation. 
Antagonists prevent the interlobe closure (Armstrong and Gouaux, 2000; Furukawa 
and Gouaux, 2003; Inanobe et al., 2005). The crystal structure of the NMDA receptor 
ligand binding domain with the high affinity GluN1 antagonist 5,7-DCKA adopts a 
conformation in which domain S1 and S2 are open by 24° (Furukawa and Gouaux, 
2003). 5,7-DCKA seems to stabilize an open cleft conformation, which is in 
concordance with previous observations of antagonists (Armstrong and Gouaux, 2000). 
In AMPA receptors there is a relationship between ligand binding domain closure and 
ion channel activation (Armstrong et al., 2003). The observed differences in 
potentiation strength with high and low affinity GluN1 antagonists at GluN1/GluN3A 
receptors possibly result from differences in domain configuration pertaining to closed 
or open state. But the ligand binding domain in complex with the weak GluN1 
antagonist Cycloleucine adopts an open cleft conformation most similar to the GluN1 
S1S2 complex with 5,7-DCKA (Inanobe et al., 2005). Consequently the potentiation 
effect of GluN1GluN3A receptors with GluN1 antagonists has to be independent of the 
degree of domain closure.  
Our results present strong evidence for a correlation between the affinity of the GluN1 
antagonists and the potentiation strength. With higher affinity of the GluN1 antagonist 
there is an increase of efficacy of GluN1GluN3A receptor currents. The high affinity 
GluN1 antagonists showed a strong potentiation in the range of 60-80 fold 
enhancement of receptor currents, whereas the low affinity GluN1 antagonist like 
kynurenic acid shows also potentiation effects but in the lower range of 4 fold 
potentiation. The correlation between the degree of potentiation and the affinity has to 
be elucidated with further GluN1 antagonists. Trough the correlation of the x-fold  
 
 111 
 
 
potentiation with the GluN1 antagonist affinity, it could be possible to predict the extend 
of potentiation strength with other or new antagonists.  
 
The potentiation effect through GluN1 antagonists is an interesting characteristic of 
GluN1/GluN3A receptors. Because the GluN1 antagonist kynurenic acid occurs 
endogenously in the brain, it is necessary to understand the impact of antagonist and 
their physiological relevance. Kynurenic acid is an end-product of the kynurenine 
pathway, in which more than 95 % of the amino acid tryptophan is metabolized (Vecsei 
et al., 2013). Kynurenic acid has proved to be a neuroprotective molecule in various 
experimental models of neurotoxicity (Winn et al., 1991). The halogenated derivatives 
7-CKA and 5,7-DCKA are promising compounds in prodrug concepts. 4-
chlorokynurenine is the blood brain barrier penetrante prodrug of 7-CKA and 
investigated in preclinical studies. It represents one of the most advanced L-kynurenine 
prodrug candidates for the use as a neuroprotective agent (Vecsei et al., 2013). The 
knowledge of antagonist agency at GluN1/GluN3A receptors is very important and 
could be essential in the future, because of the involvement of NMDA receptors in 
several neurological disorders and the use of NMDA antagonists in therapy treatment. 
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6 Discussion 
6.1 Epilepsy and ion channels 
It is well established that alterations in central inhibitory and excitatory 
neurotransmission play a crucial role in the etiology of epilepsy. In the last years a 
number of epileptogenic mutations were identified in genes, encoding for voltage – or 
ligand-gated ion channels (Noebels, 2003). There have been mutations in the nicotinic 
acetylcholine receptor subunits (De Fusco et al., 2000), in the voltage-gated potassium 
channel subunits (Leppert and Singh, 1999), in the GABAA receptor (Galanopoulou, 
2010) and in the voltage-gated sodium channel genes (Oliva et al., 2012), which 
underlie different forms of genetic epilepsies. The focus on ion channels is reasonable 
because they play a crucial role in neurotransmission and are involved in excitatory 
and inhibitory signal transmission. A gain-of-function of ion channels in excitatory 
neurotransmission could lead to hyperexcitation while a loss-of-function in inhibitory 
transmission impairs the neuronal inhibitory system. Both can result in epileptic 
seizures.  
Changes in NMDA receptor signaling have been demonstrated with animal models and 
the recent findings of mutations in the GRIN2 genes in patients with epilepsy 
syndromes provided evidence for a crucial role of NMDA receptors in epilepsy. The 
three publications (Endele et al., 2010; Lemke et al., 2013a; Lemke et al., 2013b) 
identified de novo mutations in the GRIN2A and GRIN2B gene, which encode the 
GluN2A and GluN2B subunits of the NMDA receptor. The mutations were found in 
patients with variable neurodevelopmental phenotypes e.g. epilepsy and/or mental 
retardation. They are located in different domains of the receptor and influence channel 
properties and allosteric modulation of the NMDA receptors. Because of the 
fundamental role of the GluN2 subunits for physiological and pathophysiological 
processes in the CNS and the unique role for receptor function, I focused my 
investigations on mutations in the GluN2A and GluN2B subunits, especially in the NTD 
and the pore region. 
In Table 6.1 all analyzed mutations are listed with informations about the amino acid 
substitution, the affected domain, the functional results, the phenotype, the supposed 
functional impact and the origin of mutation. 
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Table 6. 1: Summary of the analyzed epilepsy associated mutations with information about the 
amino acid substitution, the affected domain, the functional results, the patient`s 
phenotype, the supposed functional impact and the origin of mutation. (n.d. = not 
determined) 
 
 
6.2 The N-terminal domain and allosteric modulation 
The NTD is the largest domain of the NMDA receptor and has modular influence on 
receptor function. Binding of allosteric modulators occurs at the NTD of GluN2 
containing receptors, but the physiological role of the NTD of NMDA receptors is 
largely unkown. The results of the GluN2A NTD mutation may have implications for 
understanding how the NTD of NMDA receptors is involved in NMDA receptor function 
in pathological states. Sequence analysis revealed that the mutation c.728C>T in the 
GRIN2A, causes the substitution alanine to valine at the position 243 (p.Ala243Val) in 
the GluN2A subunit. This mutation was found in a patient with the epilepsy syndrome 
BECTS (benign epilepsy with centro-temporal spikes) and learning difficulties. The 
functional analysis revealed no changes in maximal inducible currents, agonist affinities 
and relative open probabilities of the mutated receptors but a loss of high-affinity 
inhibition by Zn2+ (Lemke et al, 2013b). The p.Ala243Val mutation is located in the Zn2+ 
binding NTD of the GluN2A subunit and leads to a reduced Zn2+ inhibition. Zn2+  
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inhibition occurs at physiologically relevant zinc levels and/or during co-release of Zn2+ 
with glutamate, which implicates a crucial role in physiological and pathophysiological 
processes (Assaf and Chung, 1984; Howell et al., 1984). Because of the inhibitory 
effect of Zn2+ on recombinant GluN1/GluN2 receptors (Kutsuwada et al., 1992; Meguro 
et al., 1992) and the high Zn2+ sensitivity of GluN2A-containing receptors, it is 
conceivable that under physiological conditions the receptor is tonically inhibited and 
Zn2+ has protective function against NMDA receptor-mediated overexcitation and 
glutamate toxicity. The loss of the regulatory high affinity Zn2+ inhibition in the mutated 
receptor could lead to repeated activation and enhanced Ca2+ influx. It is possible that 
this gain of function of the receptor leads to an overactivation, which could finally result 
in epilepsy syndromes. 
Mutagenesis studies showed that the bilobate NTD of the GluN2 subunit oscillates 
spontaneously between open-cleft and close-cleft conformations and influences the 
gating properties of the receptor (Gielen et al., 2009). Binding of allosteric modulators, 
e.g. Zn2+, is thought to stabilize the closed conformation and thereby weakens the LBD-
interaction, which results in a subsequent closure of the channel. The crystal structure 
of the isolated GluN2B NTD reveals the Zn2+ binding site to be within the cleft of the R1 
and R2 lobes and stabilizes a closed cleft conformation (Karakas et al., 2009). Based 
on mutagenesis studies, it is known that the zinc binding site is located at the similar 
cleft of the GluN2A NTD (Fayyazuddin et al., 2000). Regarding the NTD mutation 
(GluN2A p.Ala243Val) the question arises, if there is a disturbance of zinc binding or a 
disturbance of the zinc inhibition mechanism in the mutated receptor complex, which 
leads to the reduction of zinc inhibition. Because the residue alanine 243 is not in direct 
contact with the Zn2+ ion, the substitution seems not to influence the zinc binding itself. 
Probably the substitution of alanine to valine changes the structure of the NTD or the 
binding pocket. The Zn2+ inhibition mediated by the NTDs has to be transduced into 
alterations in channel gate activity and the closure of the NTD is a crucial step in this 
inhibition mechansim. Perhaps the mutation destabilizes the architecture of the Zn2+ 
binding pocket or the entire NTD clamshell, so that it cannot persist in the closed 
conformation or cannot close completely, which results in reduced zinc inhibition. 
Another possibility could be that the substitution leads to a conformational change of 
the NTD so that the Zn2+ ions cannot bind efficently in the clamshell cleft. To clarify the 
exact mechanism of the reduced Zn2+ inhibition further experiments are required to 
establish the role of this NTD mutation site in allosteric zinc modulation. Nevertheless 
the GluN2A NTD mutation reveals the crucial role of Zn2+ inhibition in glutamatergic  
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neurotransmission and the involvment in pathological conditions. 
 
The in vivo relevance of Zn2+ neuromodulation has already been shown in another 
ligand gated receptor, in the α1 glycine receptor, which belongs to the Cys loop 
receptor family. The Zn2+ binding site was shown to be localized in the N-terminal 
domain of glycine receptor α subunits (Laube, 2002; Lynch, 2004). A substitution of a 
single amino acid in the α1 subunit gene in the NTD eliminated the potentiating effect 
of Zn2+ on glycine receptor currents. Homozygous mice containing this mutation 
developed a severe neuromotor phenotype after birth, which leads to hyperekplexia 
also called startle disease (Hirzel et al., 2006).  
 
 
6.3 The ion channel pore 
The ion channel of glutamate receptors consists of a water-filled pore, which is divided 
in an external and internal cavity. These cavities are separated through the narrow 
constriction of the pore. The residues lining the pore build the permeation pathway and 
are the primary determinants of ion selectivity and conductance. The recently published 
crystal structure of the GluN1/GluN2B NMDA receptor refines the picture of the 
channel pore of NMDA receptors. The structure revealed a three-part arrangement in a 
gate, a vestibule and a filter section (Lee et al., 2014). A known important key 
determinant of conductance and permeation of all glutamate receptors is the identity of 
the residues at the apex of the P-loop, the so called QRN site. In AMPA and Kainate 
receptors there is a glutamine (Q) unedited or an arginine (R) edited, in GluN1 and 
GluN2 NMDA receptors an asparagine (N) and in GluN3 a glycine (G). The crystal 
structure of the full length NMDA receptor confirms these important localization and 
represents this residue at the second constriction of the channel pore at the turn 
between the end of the P helices and the beginning of the extended filter sequence 
(Lee et al., 2014). 
Within the group of ionotropic glutamate receptors, NMDA receptors exhibit a unique 
permeation profile because of their high Ca2+ permeability and the voltage-dependent 
Mg2+ block. In GluN1/GluN2 NMDA receptors the QRN site asparagine of GluN1 and 
the asparagine adjacent to the QRN site (N+1) in GluN2 formed the narrow constriction 
of the ion channel (Wollmuth et al., 1996) and single amino acid substitutions have 
shown that interactions at or near the QRN site are critical for Ca2+ permeability and 
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Mg2+ block. 
The detected de novo GRIN2A mutation Asn615Lys (c.1845C>A) (Endele et al., 2010) 
leads to the amino acid substitution asparagine to lysine at position 615 (p.Asn615Lys) 
in the mature protein. This mutation was found in a patient (3 year old girl) with early-
onset encephalopathy. The mutation Asn615Lys is located in the transmembrane 
domain in the re-entrant loop (P-loop) and is the asparagine at the QRN+1 site 
(GluN2A Asn615). In the functional analyses the substitution results in a loss of the 
Mg2+ block and a decrease in Ca2+ permeability (Endele et al., 2010). Introducing a 
positive side chain through the substitution of the amino acid lysine in the channel pore 
at this critical position, could have a repulsive effect on cation permeability and could 
explain the reduced Ca2+ permeability. Furthermore, Wollmuth and colleagues showed 
volume specific effects on the pore size with mutations at the QRN+1 site in 
GluN1/GluN2A receptors (Wollmuth et al., 1996). Supposably the lysine leads to a 
decrease in pore size, which also could influence the channel properties, finally leading 
to the reduced Ca2+ permeability. 
Interestingly sequence analysis of the GluN2B gene in two patients with West 
syndrome revealed de novo mutations in the channel pore also at the QRN site. One 
patient carries the de novo mutation c.1844 A>T in GRIN2B, which leads to the 
substitution asparagine to isoleucine at the position 615 in the GluN2B subunit 
(GluN2B p.Asn615Ile) (Lemke et al., 2013a). This substitution is the asparagine at the 
QRN site in GluN2B. The other patient carries the de novo mutation c.1853 T>G in 
GRIN2B, which results in a substitution of valine to glycine at the position 618 in the 
GluN2B subunit (GluN2B p.Val618Gly) (Lemke et al., 2013a). By functional analysis 
both mutations in the GluN2B revealed an increase in Ca2+ permeability and a reduced 
Mg2+ block.  
The mutated asparagine residues at the QRN and QRN+1 site are situated in a 
position to project their side chains into aqueous vestibule in the GluN1/GluN2B crystal 
structure (Lee et al., 2014). The substitution of the uncharged and hydrophilic 
aspargine in the narrow constriction of the pore in the GluN2B subunit (p.Asn615Ile) to 
an also uncharged but more hydrophobic isoleucine could result in strong alteration of 
side chain orientation of the isoleucine away from the inner of the pore. Thus, could 
change the characteristics of the selectivity filter and the Mg2+ block.  
The valine residue 618 is located in close vicinity to the QRN site but more in the 
middle of the pore loop. The influence in the electrophysiological analysis of this 
substitution is less than the QRN site substitution maybe because of the more distinct  
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location in the middle of the pore loop. Furthermore the substitution from the amino 
acid valine to glycine is not such a strong alteration of the side chain characteristics.  
However, the results showed that not only substitutions at the QRN site had strong 
influence on receptor function but also further residues in the middle of the pore loop. 
The results demonstrate the fundamental role of the channel residues at the QRN site 
and residues in close vicinity lining the pore loop for appropriate receptor function in 
GluN2A and GluN2B containing receptors. These observations are in concordance with 
previous studies. In mouse models, a change of these residues in the GluN1 subunit is 
not tolerated and leads to early death (Seeburg et al., 2001). Introducing an arginine at 
this position in the GRIN1 leads to Mg2+ insensitive and Ca2+ impermeable receptors in 
the mouse model (Rudhard et al., 2003). Also in other ionotropic glutamate receptors 
the QRN site is fundamental for proper receptor function. Point mutations at the QRN 
site in AMPA receptors of the GluA2 subunit lead to neonatal epileptic seizures and 
increased Ca2+ permeability (Brusa et al., 1995; Feldmeyer et al., 1999) . 
 
Through the mutations at the QRN site in both subunits (GluN2A and GluN2B) in the 
channel pore no coincidence detection is possible anymore and the coincidence-
dependent calcium signaling through NMDA receptors, which is necessary for precise 
refinement of synaptic connectivity, is disturbed. The functional analysis of the epilepsy 
associated mutations at these critical residues in the pore region of GluN2A and 
GluN2B leads to a gain of ion channel function. In neuronal networks this could lead to 
hyperexcitation in excitatory neurotransmission, finally resulting in epilepsy. 
 
In the GluN2B subunit, further mutations were found in the LBD of NMDA receptors. 
One de novo GRIN2B mutation was detected in the glutamate binding domain of the 
GluN2B subunit in a patient with moderate mental retardation. The c.2004C>T 
mutation leads to the amino acid substitution arginine to cysteine at the position 682 
(p.Arg682Cys). This residue is highly conserved within the glutamate ligand binding 
domain. In the model of the GluN2B LBD the alteration of this residue results in a loss 
of three hydrogen bonds, which destabilizes the tertiary structure of the GluN2B LBD. 
This could affect the glutamate affinity, but the functional analysis revealed no changes 
in the apparent affinity of the agonist glutamate and glycine (Endele et al., 2010). 
A further LBD mutation was detected in the GluN2B subunit in a patient with focal 
epilepsy and intellectual disability (ID). The mutation p.Arg540His leads to the 
substitution of a highly conserved arginine residue within GluN2A-D subunits. The  
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substitution to histidine influenced the Mg2+ block by a reduction of the Mg2+ 
sensitivityand led to an increased Ca2+ permeability. The structural analysis showed 
that the arginine 540 in GluN2B is essential in the stabilization of the tertiary structure 
of the glutamate binding domain. However there was no change in glutamate binding 
affinities. Unfortunately, the amino acid substitution Arg540His cannot be illustrated in 
the full length NMDA crystal structure because some residues in the loop connecting 
the LBD to the TMD are not resolved. Despite the localization in the LBD the GluN2B 
mutation p.Arg540His seems to have strong influence on the core region of the 
receptor. GluN2A and GluN2B-containing NMDA receptors are more sensitive to Mg2+ 
block than NMDA receptors that contain GluN2C and GluN2D subunits. But all four 
subunits possess an asparagine (N) residue at the QRN and QRN+1 site indicating 
that additional structural elements are required to determine the sensitivity of subtypes 
to block by Mg2+. The mutation p.Arg540His seems to have an allosteric effect and 
chimeric approaches provide evidence that the LBD of GluN2 subunits not only 
influence the agonist binding and potency but also the voltage-dependent Mg2+ block 
(Wrighton et al., 2008). Recent findings revealed also a de novo mutation in the 
GluN2B subunit in the glutamate binding site at position 461, which substitutes a 
cysteine into a phenylalanine (p.Cys461Phe) (Allen et al., 2013). The patient with the 
mutation p.Arg540His patients and the patient with the mutation (p.Cys461Phe) 
displayed similar symptoms presented with primary developmental delay and childhood 
onset epilepsy. Unfortunately, no functional data from the p.Cys461Phe mutation were 
available. Therefore, it would be very interesting to investigate the functional 
consequences and the influence on Mg2+ sensitivity as well as Ca2+ permeation. 
 
The recent findings focused on the GluN2 subunits of the NMDA receptor. Hamdan 
and colleagues identified also de novo mutations in the GRIN1, which encodes the 
essential GluN1 subunit of the NMDA receptor (Hamdan et al., 2011). The mutations 
were located in the transmembrane regions and lead to an increase of Ca2+ currents 
and an abolishment of receptor activity and were detected in patients with intellectual 
disability (ID) and epilepsy. Further GluN1 mutations were analyzed in our group in the 
context of Bachelor theses. The results showed a strong influence on receptor function 
of mutations in the transmembrane domains. These findings further support the 
involvement of further NMDA receptors subunits in epilepsy syndromes and implicated 
a strong influence of the core domains of the NMDA receptor subunits for receptor 
function and an involvement in pathological conditions. 
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6.4 NMDA mutation link to disease phenotype? 
There is great interest in determining whether different NMDA receptor subtypes make 
specific contributions to pathological neuronal processes. All epilepsy associated 
mutations were detected in patients with age-related disease phenotypes and all 
pathological mutations were detected in the developmental regulated GluN2 subunits. 
The appearance of the age-related epilepsy syndromes in combination with the 
mutations in the developmental regulated GluN2 subunits lead to the conclusion that 
the stage of brain maturation plays a crucial role in the development of epilepsy 
syndromes. A disturbance of the precise regulation mechanisms during development 
results in serious impairment.  
NMDA receptors are central in brain development and the calcium influx through 
NMDA receptors on the one hand plays a neuroprotective role but on the other hand 
could lead to excitotoxicity, which leads to cell death. Thus, the activation of these 
receptors has important implications for the survival or death of neurons, which is 
important especially in the developing brain. It was shown that blockade of NMDA 
receptors during late fetal or early neonatal life triggered apoptotic neurodegeneration 
in rats (Ikonomidou et al., 1999). Hence, it is conceivable that disturbance of the 
regulation mechanism, instead of blockade, could also lead to neurological impairment. 
Due to the gain of function mutations in the GluN2A and GluN2B subunits, it is likely 
that also increased activity during the development could result in strong impairment, 
like, epilepsy. The gain of ion channel function could be a reasonable molecular 
correlate for the epilepsy syndromes, because it results in an overactivation of the 
receptors, which is in concordance with the hypothesis that epilepsy proceeds from 
hyperexcitation.  
Based on the different physiological roles of GluN2A and the GluN2B subunits it is not 
much surprising that there occurred differences in the patient phenotypes. One 
common characteristic of the different phenotypes of patients with GluN2 subunit 
mutations is the age-dependent occurrence during the childhood, which implicates the 
crucial role of correct regulation and function of the GluN2 subunits in development.  
 
 
6.4.1 The GluN2A subunit 
Since the first identification and functional investigation of epilepsy associated 
mutations in the GluN2A subunits of the NMDA receptor (Endele et al., 2010) several 
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further GluN2A mutations in different receptor domains were detected. Yuan and 
colleagues recently identified a de novo mutation in the linker region between the 
ligand binding domain and the transmembrane domain in GluN2A in a patient with 
early-onset epileptic encephalopathy and profound developmental delay (Yuan et al., 
2014). Like the GluN2A mutation in the NTD and the ion channel pore of the NMDA 
receptor, this mutation also results in a gain of function through a strong impairment of 
receptor function with enhanced agonist potency, decreased sensitivity to magnesium, 
protons and zinc and an increased single-channel open probability. Further gain of 
function mutations in the GluN2A subunit were detected from Carvill et al. and Lesca 
and colleagues (Carvill et al., 2013; Lesca et al., 2013a). They identified mutations in 
patients with disorders of the epilepsy-aphasia spectrum.  
Despite the information about the functional impact of several GluN2A mutations, to 
date it is difficult to build a clear correlation between the different GluN2A subunit 
mutations and the appeared phenotype. The GluN2A NTD mutation (p.Ala243Val) 
occurred in a patient with BECTS (Chapter 3). This epilepsy form is the most frequent 
epileptic syndrome in children (Holmes, 1993). According to the International League 
Against Epilepsy (ILAE) BECTS is classified as idiopathic focal epilepsy. Seizure onset 
is usually aged between 3-10 years (Beaumanoir et al., 1974). In most cases the 
children have a good prediction and after adolescence there are no further seizures or 
neurospychatric abnormalities. A more severe phenotype was detected in the patient 
with early-onset encephalopathy with first seizures at the age of 3 month with the pore 
mutation GluN2A p.Asn615Lys (Chapter 2). The differences pertaining to the 
phenotypes could be due to the fact that the gain of function arises from different 
mechanisms. In the case of the mutation in the NTD (GluN2A p.Ala243Val) appeared a 
loss of the Zn2+ inhibition. This inhibition mechanism is non-competitive and, unlike 
Mg2+ block, voltage independent. Although there is no doubt that during synaptic 
activity vesicular Zn2+ is released, there is no consensus about the time course and 
amplitude of Zn2+ concentrations in the synaptic cleft (Paoletti et al., 2009). But the 
important role of synaptic Zn2+ in the pathophysiology of epilepsy could point out in 
several observations (Frederickson, 1989). So a disturbance of the Zn2+ inhibition 
mechanism in the GluN2A subunit is likely to trigger epilepsy syndromes.  
The pore mutation (GluN2A p.Asn615Lys) influences two main features of NMDA 
receptors in the functional analysis. On the one hand the mutation leads to a loss of the 
voltage dependent Mg2+ inhibition. On the other hand there is a reduced Ca2+ 
permeability. This mutation raises the question if this is a gain or loss of function. The  
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loss of the Mg2+ inhibition results in a higher susceptibility of the receptor and results in 
a loss of coincidence detection. The reduced Ca2+ permeability could result in a 
reduced pro-death signaling through a diminished phosphorylation of CREB. This could 
lead to neurodegeneration and cognitive impairment, especially in development.  
 
 
6.4.2 The GluN2B subunit 
Both mutations in the channel pore within the GluN2B subunit are found in patients with 
the West syndrome. The West syndrome is a severe form of epilepsy characterized by 
early onset (in the first year), a cluster of infantile spasms (IS) and a characteristic EEG 
pattern called hypsarrhythmia (Lagae et al., 2010; Pavone et al., 2013). In most cases 
the West syndrome has worse prediction and the treatment is relatively difficult. 
Another mutation in the GluN2B subunit, located in the LBD, was found in a patient 
with focal epilepsy and ID. The mutation in the LBD shows a milder gain of function in 
comparison to the pore mutations of the West Syndrome patients, which results in a 
stronger gain of function of the ion channel. 
Especially, GluN2B containing receptors are critical for cortical development and 
function. This could be shown through an inversion of the developmental switch from 
GluN2B to GluN2A through a genetically replacement of the GluN2B subunit by the 
GluN2A. The NMDA current is then mediated by GluN2A containing receptors in the 
absence of GluN2B (Wang et al., 2011). The early expression of GluN2A instead of 
GluN2B is unable to rescue GluN2B loss of function. This indicates that GluN2B 
containing NMDA receptors activate unique cellular processes and that the period of 
predominance of the GluN2B subunit in development is critical for the developing brain. 
The mutations in the GluN2B subunit lead to a gain of function and results in a higher 
Ca2+ permeability. Referring to the extrasynaptic localization and subsequent 
deactivation of CREB, an overactivation would result in an enhanced pro-death 
signaling (Hardingham and Bading, 2010).  
 
In summary differences in the mechanism of ion channel impairment, in regulation 
mechanisms during development and downstream pathways could be possible 
reasons for the differences in the occurred phenotypes. Generally it seems that 
mutations in the core domains of the receptor, independent from the subtype, results in 
stronger impairment of receptor function and to servere phenotypes, which are not  
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easily treatable and leads to long-lasting developmental impairment. In the case of the 
three GluN2B mutations there exists a correlation between the severity of phenotype 
and the electrophysiological impairment of receptor function. Although it is nearly 
impossible to make a prediction for the patients phenotype based on a detected 
mutation, the electrophysiological results could be useful for therapeutic treatment. 
 
 
6.5 The NMDA receptor: a promising target for therapeutic 
intervention in epilepsy 
The findings of epilepsy-associated mutations in the GRIN2A and GRIN2B lead to a 
new interest in more selective NMDA modulators in the future for possible therapeutic 
treatment. In the case of mutations, which result in a gain of function and finally result 
in an overactivity of the NMDA receptors, maybe there exists a chance to treat some 
forms of epilepsy with subunit selective antagonists. GluN2A and GluN2B subunits are 
potential targets and can be modulated by existing drugs or compounds, for example 
through the antagonist memantine. Memantine is a NMDA channel blocker and is 
already therapeutically used in Parkinson and Alzheimer therapy and shows only little 
side effects (Parsons et al., 1999; Witt et al., 2004) 
A recent paper indicates therapy potential with memantine also in epilepsy syndromes. 
In a patient with a mutation in the GluN2A subunit and early-onset encephalopathy the 
medication with memantine reduces the patients seizure burden. The cognitive ability 
remained unchanged (Pierson et al., 2014). This case create the new possibility by 
combination of high-throughput screening, electrophysiological studies and subsequent 
therapeutic screening on the mutated protein find a specific antagonist, which use 
could lead to an improvement of the course of disease. In the future it is conceivable 
that an early treatment with an appropriate NMDA antagonist could improve the 
patients development or minimize the developmental impairment in some cases of 
NMDA associated forms of epilepsy. Based on the findings of epilepsy associated 
mutations in different NMDA receptor subunits, a genetic diagnosis could be possible in 
the future and the proof of genetic defects could lead to a definitive diagnosis. This can 
be important for the prognosis and probably influence therapeutic decisions. 
Furthermore, with the knowledge of genetic defects new treatment strategies of some 
forms of epilepsies become possible in the future and perhaps the defective protein 
can be used as new pharmacological target (Weber and Lerche, 2008).  
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In some cases, the use of NMDA antagonists seems to have good prospects in 
epilepsy therapy. A fundamental problem would be that many antagonists have strong 
adverse effects or could have opposite effects on other receptor subunit combinations 
(Chapter 5). The challenge in the future would be to find subunit-selective compounds, 
which correct the abnormal activity of the protein without disturbing/changing the 
NMDAR signaling in the whole brain.  
 
 
6.6 The excitatory GluN1/GluN3A receptors 
Although GluN1/GluN2 receptors and GluN1/GluN3 receptors belong to the same 
receptor family, they display essential different pharmacological properties. In contrast 
to the conventional GluN2 containing receptors they show reduced Ca2+ permeability 
and Mg2+ sensitivity. Because of the high Ca2+ permeability of conventional NMDA 
receptors an overstimulation can induce cell death due to excessive Ca2+ influx in the 
cell. The reduced calcium permeability of GluN3A subunits emerge the idea of a 
neuroprotective role for the GluN3A subunit (Pachernegg et al., 2012). The occurrence 
of native GluN1/GluN3A receptors is controversial, but there are hints for 
GluN1/GluN3A receptors in CNS myelin (Pina-Crespo et al., 2010). A problem in 
measuring GluN1/GluN3A receptor activity in vivo is the rapid desensitization in 
response to glycine (Awobuluyi et al., 2007; Chatterton et al., 2002) and because of the 
high glycine affinity the receptor might be saturated at physiological concentrations of 
glycine. 
Despite the recent results of our findings, the exact mechanism of the potentiation 
effect of GluN1 antagonists at GluN1/GluN3A receptors, remains to be elucidated. We 
had shown the agonistic effect of GluN1 antagonists, which leads to enhanced receptor 
currents of GluN1/GluN3A receptors in an affinity dependent manner (Chapter5). 
These results of different influence on the magnitude of potentiation on receptor 
currents could be a useful tool for studying GluN1/GluN3A receptors in vivo.  
 
Special attention should be paid to the GluN1 antagonist kynurenic acid, which 
occurred endogenously in the brain. Kynurenic acid may play a physiological role in 
blocking conventional NMDA receptor activation. In the case of GluN1/GluN3A 
receptors it can enhance receptor activation. This is of interest because the GluN1 
antagonist kynurenic acid may play also a pathophysiological role in epilepsy. Studies  
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showed a decrease of kynurenic acid levels of the cerebrospinal fluid in patients with 
West syndrome (Yamamoto et al., 1995; Young et al., 1983). A chronic deficiency of 
the GluN1 antagonist could potentially lead to a developing NMDA excitotoxic process 
through conventional GluN1/GluN2 NMDA receptors, but also could have a negative 
effect through GluN1/GluN3A receptors.  
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6.7 Outlook 
Understanding the NMDA receptor function in neurological disorders is fundamental 
and could be a promising approach for the improvement of therapeutic strategies. The 
detection of epilepsy associated mutations and the electrophysiological analysis 
revealed strong impairment of receptor function and identify the NMDA receptor as a 
key player in the incidence of epilepsy syndromes. The understanding of genotype-
phenotype relationships prove to be challenging. Mutations in different domains of the 
receptor cause similar impairment of receptor function, but the mutations cause 
different phenotypes. Further investigations are needed to elucidate the role of 
mutations in different receptor subunits and a possible influence on receptor function. 
Knowledge of the genetic defect and their underlying mechanism can give rise to new 
therapeutic strategies. Further physiological characterization of epilepsy associated 
mutations in cell culture and animal models for studying hippocampal slices and brain 
physiology could be considered, because data of relative simple expression systems 
lack the complexity of neurons. Also the in vivo relevance for changes in ion channel 
behaviour observed in vitro has to be elucidated. Studies in knock in mice could be a 
possibility for deeper understanding of mechanisms not only in vitro but also in vivo. 
Especially, in regard to the developmental influence of mutations in the GluN2 
subunits, in vivo studies in mice could recapitulate the human genotype and 
phenotype.  
The results from this work put the NMDA receptors in perspective as novel therapeutic 
target in epilepsy syndromes in personalized therapy. Further experiments to detect 
and to understand the antagonist mechanism on different mutations in various receptor 
combinations could lead to promising therapeutic strategies. For example, the GluN2A 
p.Asn615Lys mutation responded in electrophysiological experiments not to the 
antagonist memantin, but to other antagonists (dextromethorphan and dextrorphan) 
(Pierson et al., 2014). This indicates a need for specific electrophysiological evaluation 
of the mutations and raises the possibility that treatment with the proper antagonist can 
help to select the best therapy.  
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